

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024361
Article Type:	Research
Date Submitted by the Author:	23-May-2018
Complete List of Authors:	Stack, Rebecca; Nottingham Trent University , Division of Psychology Nightingale, Peter; Queen Elizabeth Hospital Birmingham, Wellcome Trust Clinical Research Facility Jinks, Clare; Keele University, Arthritis Research UK Primary Care Centre Shaw, Karen; University of Birmingham, Institute of Applied Health Research Herron-Marx, Sandy; Independent Research Consultant Horne, Rob; UCL, UCL School of Pharmacy Deighton, Chris; Derby Teaching Hospitals NHS Foundation Trust Kiely, Patrick ; St George's University Hospitals NHS Foundation Trust Mallen, Christian; Keele University, Arthritis Research UK Primary Care Centre Raza, Karim; University of Birmingham, Institute of Inflammation and Ageing
Keywords:	RHEUMATOLOGY, access to care, help seeking, health service research, rheumatoid arthritis

SCHOLARONE™
Manuscripts

1
2
3 **Title: Delays between the onset of symptoms and first rheumatology consultation in**
4
5 **patients with rheumatoid arthritis in the UK**
6
7

8
9
10 **Authors**

11 Rebecca J Stack^{1,2}, Peter Nightingale³, Clare Jinks⁴, (DELAY study syndicate), Karen Shaw⁵,
12
13 Sandy Herron-Marx⁶, Rob Horne⁷, Patrick Kiely⁸, Chris Deighton⁹, Christian D Mallen⁴ and
14
15 Karim Raza^{1,10}
16
17
18
19
20

21 **Department and Institutions**
22

- 23 1. Institute of Inflammation and Ageing, University of Birmingham, UK.
24
25 2. Division of Psychology, Nottingham Trent University, Nottingham, UK
26
27 3. Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation
28
29 Trust, Birmingham, UK.
30
31 4. Research Institute for Primary Care and Health Sciences, Keele University, UK.
32
33 5. Institute of Applied Health Research, University of Birmingham, UK
34
35 6. Independent Research Consultant, Brussels, Belgium.
36
37 7. School of Pharmacy, University of London, UK.
38
39 8. Department of Rheumatology, St Georges University Hospital NHS Foundation Trust,
40
41 London, UK.
42
43 9. Department of Rheumatology, Derby Hospitals NHS Foundation Trust, Derby, UK.
44
45 10. Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust,
46
47 Birmingham, UK.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Word Count** (excluding title page, abstract, references, figures and tables): 2499
4
5
6
7

8
9 **Keywords**

10
11 Rheumatoid arthritis; patient delay; Primary care delay; help-seeking; access to care;
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths of this study.

This study surveyed a large sample of patients with new onset rheumatoid arthritis in the UK to identify delays in access to care.

This study identified that approximately 20% of patients saw a rheumatologist within 12 weeks of symptom onset, and factors associated with slower self-referral and slower GP referral were identified.

Limitations of this study.

Data was collected at the point of diagnosis from multiple sources including medical records and patient recall, future research should examine those at risk and follow their journey to diagnosis to avoid the limitations of retrospective data collection.

This research has identified factors associated with delays, however, further research is needed to identify factors which would speed up self-referral, GP referral and hospital waiting times for those experiencing early symptoms.

Abstract

Objective: To investigate delays to rheumatology assessment for patients with a new onset of rheumatoid arthritis (RA)

Methods: Newly presenting adults with either RA or unclassified arthritis were recruited from rheumatology clinics. Data on the length of time between symptom onset and first seeing a GP (patient delay), between first seeing a GP and being referred to a rheumatologist (primary care delay) and being seen by a rheumatologist following referral (secondary care delay) were captured.

Results: 822 patients participated (563 female, mean age 55 years). The median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4–26.3 weeks). Patients who purchased over the counter medications or used ice/heat packs took longer to seek help. In addition, those with a palindromic or an insidious symptom onset delayed for longer. The median primary care delay was 6.9 weeks (IQR 2.3–20.3 weeks). Patients made a mean of 4 GP visits before being referred. The median secondary care delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Conclusion: This study identified delays at all levels in the pathway towards assessment by a Rheumatologist. However, delays in primary care were particularly long. Patient delay was driven by the nature of symptom onset. Complex multi-faceted interventions to promote rapid help seeking and to facilitate prompt onward referral from primary care should be developed.

Introduction:

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately 1% of the population.^{1;2} Rheumatoid arthritis is associated with significant morbidity and reduced life expectancy, in large part as a consequence of extra-articular co-morbidities associated with systemic inflammation. In the UK it has been estimated that RA costs the NHS around £560 million per year and that additional costs to the economy of sick leave and work-related disability total £1.8 billion per year.³ The first three months following the onset of RA symptoms represents an important therapeutic window.⁴ Treatment during this phase improves long-term clinical outcomes, increasing the proportion of patients whose disease enters remission, reducing RA related joint damage and reducing the eventual need for joint replacement surgery.⁵⁻¹⁰ Therefore, it is vital that patients are seen by Rheumatologists rapidly following the onset of RA symptoms. However, despite increased recognition of the benefits of early treatment there remains considerable delay between symptom onset and the initiation of therapy.¹¹⁻¹³ Indeed a report by the UK's National Audit Office (NAO) in 2009 estimated that only 10% of patients with RA were treated within three months of symptom onset. The NAO's modelling suggested significant financial benefits for the broader economy and quality of life benefits for the individual if the proportion of patients treated earlier was increased.³

The patient's pathway to care can be delayed for a number of reasons, including delays on the part of the patient in recognising the significance of the early symptoms of RA.¹⁴⁻¹⁶

Recent research has linked patients' perceptions of RA and coping styles to the length of

1
2
3 time taken to seek help.¹⁷ Before seeking medical help from a physician, patients may seek
4
5 help from a range of services including complementary therapists, pharmacists and
6
7 telephone and on-line services. However, the use of these services at the onset of
8
9 inflammatory arthritis has not been fully explored. Primary healthcare professionals often
10
11 find the early symptoms of RA difficult to distinguish from those of other rheumatic
12
13 diseases, making timely and appropriate referrals to rheumatologists challenging.^{18;19} There
14
15 may thus be delays in healthcare professionals making a referral to a Rheumatologist and
16
17 also in assessment at the secondary care level, contributing further to the delay in making a
18
19 diagnosis and commencing appropriate therapy.
20
21
22
23
24
25

26 Several studies conducted across a range of countries have shown long delays between the
27
28 onset of symptoms and a patient's first consultation with a rheumatologist.²⁰⁻²³ However,
29
30 data related to lengths of time between the onset of inflammatory musculoskeletal
31
32 symptoms and first seeing a GP, between first seeing a GP and being referred to a
33
34 rheumatologist and being seen by a rheumatologist following referral are not yet available
35
36 across multiple NHS Trusts in multiple regions of the UK.
37
38
39
40
41

42 **Aim**

43
44 The aim of this study was to investigate the extent of delay in assessment of patients with
45
46 RA in England and Scotland. Specifically the study assessed lengths of delay at pre-primary
47
48 care, primary care and secondary care levels, exploring the relationships between lengths of
49
50 delay and demographic variables and capturing data relating to sources of information, help
51
52 and advice utilized by patients prior to GP consultation.
53
54
55
56
57
58
59
60

Methods

A questionnaire based survey of consecutively presenting patients with a new onset of RA or unclassified inflammatory arthritis was undertaken in England and Scotland. Networks such as the Early Rheumatoid Arthritis Network and Clinical Research Network were used identify Rheumatology centres to participate in this study. RJS also promoted the study during abstract presentations at British Society for Rheumatology meetings.

Data were collected from Rheumatology departments in 34 NHS Trusts. Rheumatology departments were secondary care based, although one rheumatology department operated clinics in both hospital and community settings. Eligible patients were recruited on their first or second visit to the rheumatology department following a primary care referral. Rheumatologists were asked to approach consecutively presenting patients who met the eligibility criteria. Eligible patients were newly referred adults (aged ≥ 18 years) with clinically apparent synovial swelling of one or more joints who had either a new onset of RA (according to 2010 ACR / EULAR criteria²⁴) or unclassified arthritis (UA; defined as a failure to fulfil classification criteria for another inflammatory rheumatic disease). Patients with UA were recruited, as in many cases patients with UA at initial secondary care assessment progress to RA over time.²⁵

Data were collected using two questionnaires. First, following consent, the recruiting healthcare professional completed a brief questionnaire that captured data on extents of delays between [1] symptom onset and seeing a healthcare professional (from herein referred to as 'patient delay', these data was gathered from the patient's account by the recruiting healthcare professional), [2] seeing a healthcare professional and being referred

1
2
3 to a rheumatologist (from herein referred to as 'primary care delay', these data was
4
5 gathered from the patient's account by the recruiting healthcare professional), and [3] being
6
7 referred to a rheumatologist and seeing a rheumatologist (from herein referred to as
8
9 'secondary care delay', these data were gathered from referral letters and hospital notes).
10
11 Data were also collected on demographic variables including the patient's age, gender,
12
13 education, employment status and postcode; deprivation ranks were calculated from
14
15 postcode data using Geoconvert 2010 which produced an Index of Multiple Deprivation
16
17 (IMD) score.²⁶ Data were gathered on the mode and rapidity of symptom onset
18
19 (palindromic (defined as intermittent symptoms) vs. non-palindromic and acute vs.
20
21 insidious). In addition, clinical data relating to duration of morning stiffness, swollen and
22
23 tender joint counts, Disease Activity Score 28 (DAS28) and fulfilment of 2010 ACR/EULAR
24
25 criteria for classification of RA²⁴ were collected at the time of assessment in secondary care.
26
27 Questionnaires were returned to a named researcher (RJS) at the University of Birmingham
28
29 for data entry and analysis using SPSS.²⁷
30
31
32
33
34
35
36

37 Patients were asked to provide data on actions taken in relation to their symptoms prior to
38
39 seeking help in primary care as part of a separate patient completed questionnaire. The
40
41 questions included in that questionnaire were informed by previous qualitative research,
42
43 including patient interviews and interviews with healthcare professionals. In addition, we
44
45 had input from Patient Research Partners and the questions asked were validated and
46
47 assessed for reliability²⁸.
48
49
50
51
52
53
54
55
56
57
58
59
60

Analysis

To ensure that the data met parametric assumptions, the distribution and levels of multicollinearity between variables were checked. Data on patient, primary care and secondary care delays were not normally distributed, therefore, log values of these delay data were created to generate normally distributed variables.

An Analysis of Variance assessed the main effects and two-way interactions for patient delay, primary care delay and secondary care delay between the following variables: gender, ethnicity, IMD score, age, education, employment status, palindromic onset, acute onset, patient reported family history of RA, and RA vs. UA. Two-way interactions which were not significant were removed in a backwards stepwise fashion, with the pairings with the highest p values being removed first, but all main effects were retained, so that the final model included all ten explanatory variables and any significant two-way interactions ($p < 0.01$).

Results

1. Participant characteristics

Data were collected from 856 patients between 2011 and 2014. Patients were withdrawn from the study due to incomplete data (21 cases) and ineligibility (13 cases in whom there was no clinical synovitis reported at recruitment). Data were thus analysed from 822 patients of whom 68.5% were female with a mean age of 55 years. Characteristics of patients are presented in table 1.

Table 1: Demographic and disease related characteristics of patients . Data are presented as either percentage (number) or median (IQR) as appropriate. Tender joint count is out of 42 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 hip, 2 knee, 2 ankle, 10 MTP). Swollen joint count is out of 40 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 knee, 2 ankle, 10 MTP).

Female	68.5% (563)
Age, years	57 (45-67)
Diagnosis of RA	43% (368)
Ethnicity:	
Black British	6.0% (49)
South Asian	7.7% (63)
White British	84.9% (698)
Other	1.5% (12)
Self-reported family history of RA	34.9% (287)
Palindromic onset	42.8% (352)
Acute onset	35.9% (295)
Duration of morning stiffness, minutes	60 (10-120)
DAS28	4.88 (3.98 -5.80)

HAQ	1.13 (0.50-1.73)
Tender joint count	9 (4-18)
Swollen joint count	5 (2-10)

2. Intervals between symptom onset and first rheumatology consultation

Overall the median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1 – 66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks). The median primary care delay was 6.9 weeks (IQR 2.3–20.3 weeks) with patients making a mean of 4 GP visits before being referred. The median secondary care delay was 4.7 weeks (IQR 2.9–7.5 weeks). Data are shown in Figure 1.

Patients with a palindromic symptom onset had a significantly longer patient delay than those with a non-palindromic onset (9.3 weeks (IQR 2-43 weeks) vs 4.3 weeks (IQR 1-17 weeks); $p < 0.001$, t-test). Furthermore, those with an acute symptom onset had significantly shorter patient delays than those with an insidious symptoms onset (2.4 weeks (IQR 1 - 6.6 weeks) vs 11.1 weeks (IQR 4-44 weeks; $p < 0.001$, t-test).

Resources used before seeking help from primary care

Patients reported taking a range of actions in relation to their symptoms before seeking help from their GP and in some cases these actions were associated with longer delays in GP consultation (see table 2). Most often patients reported purchasing tablets from 'the chemist', although only a small proportion actually reported speaking to a pharmacist. Other actions reported by patients included applying heat or cold packs to joints or buying joint supports.

Table 2. *Actions taken by patients with inflammatory arthritis before seeking help from their GP with comparison made for patient delay between those who did and did not undertake this action using independent t-tests; * P value for comparison of those who did and did not undertake this action.*

Actions taken before seeking help from GP	% (number) of participants undertaking this action	Median (IQR) patient delay in weeks for those undertaking this action	Median (IQR) patient delay in weeks for those not undertaking this action	P value
Bought tablets from the chemist	51.1% (273 out of 534)	6.9 (2-30.7)	4.7 (1.4-23)	p=0.036
Used an ice or heat pack on joint	47.8% (254 out of 531)	7.6 (2-30.3)	4.9 (2-26.1)	p=0.045
Took baths	47.4% (251 out of 529)	6.3 (2-30.4)	5.6 (2-26.1)	p=0.473
Bought joint supports	37.4%	4.4 (2.1-18.6)	5.1 (2-26.9)	p=0.362

(splints, tubi-grips etc)	(198 out of 529)			
Used alternative therapies	25.2% (134 out of 531)	8.3 (2-42.1)	5.3 (2-26.3)	p=0.020
Bought products from a health shop	19.0% (101 out of 532)	5.9 (2-36.3)	5.9 (2-26)	p=0.182
Modified diet	14.4% (76 out of 529)	6 (2.1-35.3)	6.1(2-26.3)	p= 0.183
Used prayer or sought spiritual guidance	8.4% (45 out of 534)	4.4 (2.1-18.6)	6.3 (2-26.9)	p=0.941
Spoke to a pharmacist	7.9% (41 out of 521)	5.9 (2-38.1)	5.9 (2-26.3)	p=0.544

Thirty-seven percent of patients reported looking on the internet (for example visiting the NHS direct website, BUPA website, Arthritis Research UK website and searching for information using search engines such as Google). Patients also reported seeking support via a telephone helpline; 5.7% described calling the NHS direct helpline or another telephone health advice service. Whilst, in the vast majority of cases, the GP was the first healthcare professional consulted by the patient, 3.7% sought help in the workplace (e.g. from an occupational nurse), 2% of patients went directly to A&E and 1% attended an NHS walk-in centre.

Multivariate analysis: Patient delay

The interaction model showed main effects for mode of onset (palindromic vs. non-palindromic; $F=26.65$, $P<0.01$) and rapidity of onset (acute vs. insidious; $F= 65.36$, $P<0.01$).

An interaction was found between mode of onset and gender ($F=45.658$, $P<0.01$); men with a palindromic onset waited for longer before seeking help (Figure 2).

Multivariate analysis: GP delay

A main effect was found for ethnicity ($F=6.26$, $P<0.01$). Significant differences in primary care delay were found between White British and South Asian patients (6.2 weeks (IQR 2-18.6) vs 22 weeks (IQR 6.5-39.8); $P<0.001$) and between White British and Black British patients (6.2 weeks (IQR 2-18.6) vs 11.1 weeks (IQR 4.3-21.7); $P<0.001$). No significant difference was found between South Asian and Black British patients ($P=1.000$).

A main effect was also found for family history ($F=5.89$, $P<0.01$); the median primary care delay for those with a self-reported family history of RA was 9 weeks (IQR 2.4-25.7), while primary care delay for those with no family history was 6.3 weeks (IQR 2.3-19). Interactions at a statistically significant level (<0.01) were not found.

Multivariate analysis: Secondary care delay

The original model included main effects and two-way interactions for the following explanatory variables: gender, ethnicity, IMD score, age, education, employment status, mode of onset, rapidity of onset, family onset and RA vs. UA. None of the main effects or interactions (when removed backwards) were significant in predicting the delay between referral and being seen in secondary care.

Discussion

International guidelines recommend that the treatment of RA should begin as soon as possible after the onset of symptoms, ideally aiming to capture patients within the first 3 months following symptom onset. However, this large UK study of delays in access to care for RA patients found that the median patient delay in seeking help at the onset of symptoms was 5.4 weeks, while the median delay between seeing a healthcare professional and being referred was 6.9 weeks. Our study highlights that only 20% of patients were seen within the first 3 months of symptom onset. This appears to be much lower than the rate reported in other European countries for example a recent study in Austria reported at 38% of patients were seen within the first 3 months²⁹. The present study also found an average delay of 4.7 weeks from referral until the patient was seen by a rheumatologist, similar to figures reported in the NOA report³. Unlike other some previous studies conducted in the UK,^{3;12} we found that GP delay was the largest contributor to overall delay.

This research highlights that delays in primary care are long, and a major contributor to overall delays between symptom onset and the first rheumatology visit. General practitioners are faced with a number of barriers to identifying patients with newly presenting RA including the often non-specific nature of symptoms at the earliest stages of RA.¹⁸ Research is underway to define symptom complexes most predictive of RA development in patients with newly presenting musculoskeletal symptoms and it is likely that a combination of education, and evidence based referral algorithms, will be needed to ensure that suspected cases are referred early. For example, in Fife, Scotland GPs do not have access to rheumatoid factor testing, and use guidelines with pictorial representations

1
2
3 to help identify early synovitis (personal communication Dr Helen Harris). Fife was a
4
5 participating centre in this study, and was found to have the lowest GP referral time of all
6
7 centres surveyed. Furthermore, facilitating access to secondary care, for example through
8
9 the establishment of rapid assessment clinics whose main aim is to identify whether the
10
11 patient does or does not have synovitis have been shown to significantly reduce delays in
12
13 the assessment of patients.³⁰ A limitation of our research is that the study was not able to
14
15 assess regional differences across NHS Trust in England and Scotland. A study comparing
16
17 delays and referral patterns between NHS Trusts with local policies and practices which may
18
19 influence the time between onset and first consultation would be welcome.
20
21
22
23
24
25

26 A number of factors were found to influence GP delay, including ethnicity and deprivation.
27
28 Studies in the field of oncology have also found that people from ethnic minority
29
30 backgrounds face longer GP delays,^{31;32} and that GPs working in more deprived communities
31
32 take longer to make referrals.³³ In the context of RA it is possible that the early
33
34 symptomatology of patients from ethnic minority backgrounds is different from, and less
35
36 typical of RA than that of, patients of white British background, thus making recognition
37
38 more challenging for GPs. Data certainly exist that the clinical phenotype of established RA
39
40 differs in patients of South Asian origin compared with patients of White British origin,³⁴
41
42 though data relating the clinical presentations of RA in these groups are lacking.
43
44
45 Furthermore, it is unclear why a self-reported family history of RA would be associated with
46
47 longer delays although it is important to recognise that GPs may not have elicited this
48
49 information from the patient.³⁵
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Previous qualitative studies and a meta-synthesis have identified barriers to help seeking at
4
5 the onset of RA.³⁶⁻³⁹ The present study identifies that before seeking formal medical
6
7 attention, people experiencing the early symptoms of RA seek information and help from a
8
9 number of alternative sources and often self-medicate. We identified that buying tablets
10
11 from a pharmacy, and using heat or ice on joints was significantly associated with longer
12
13 patient delays. This finding highlights that some self-management behaviours, particularly
14
15 those linked to accessing pharmacy services can negatively impact on the time it takes to
16
17 seek help; this needs further exploration. Factors previously suggested to be associated
18
19 with delays in GP consultation included an insidious onset of mild symptoms and a lack of
20
21 knowledge about RA, personal susceptibility to RA and the availability of treatments to slow
22
23 disease progression. In our national sample 64.1% of people describe an insidious onset of
24
25 RA, and 42.8% describe a palindromic onset of RA. Therefore, the majority of patients
26
27 surveyed experienced a slow and / or intermittent onset of their RA symptoms. Our
28
29 quantitative data are thus consistent with results from qualitative studies, demonstrating
30
31 that the mode and rapidity of onset of symptoms is significantly associated with patient
32
33 delays.
34
35
36
37
38
39
40
41

42 Whilst delays in primary care are the largest contributor to overall delay, patient delay and
43
44 secondary care delay represent important components. This study found that the nature of
45
46 symptoms onset influenced how quickly patients with RA sought help, suggesting that those
47
48 with an acute onset of persistent symptoms seek help faster than those with insidious and
49
50 palindromic onsets. Interventions to encourage rapid help seeking should consider
51
52 highlighting the frequently insidious onset of RA to members of the public stressing that
53
54 help should be sought even when symptoms are mild.
55
56
57
58
59
60

1
2
3
4
5 Interventions at multiple levels, including at the levels of the public, the services which the
6
7 public consult after the onset of symptoms (e.g. pharmacies), primary care and secondary
8
9 care will be needed to reduce overall delays in access to appropriate specialists.
10
11

12 13 14 15 **Limitations**

16
17
18 This study has a number of limitations. Firstly, the interval between first consultation with a
19
20 Rheumatologist and initiation of disease modifying anti-rheumatic drug (DMARD) treatment
21
22 was not measured. Any additional delay in commencing DMARD treatment will negatively
23
24 impact the patient and variables associated with delays at this level should be assessed in
25
26 future studies.
27
28

29
30 During the course of this study a number of guidelines were published which may have
31
32 influenced practice, and patterns of referral. However, the rate of recruitment over time
33
34 was not controlled e.g. at the start of the study recruitment was slow, and then increased
35
36 later as more centres participated. Future investigation should assess the impact of policy
37
38 changes on patterns of help-seeking, referral and assessment.
39
40
41

42
43 The rheumatology centres participating in this study were self-selecting, therefore, there
44
45 may be biases in the characteristics of the rheumatology centres which participated in this
46
47 study. For example, the participating rheumatology units may have had a particular interest
48
49 in early arthritis. Only a study which recruited consecutive patients from all rheumatology
50
51 units across the UK would be able to provide a truly national picture.
52
53
54
55
56
57
58
59
60

1
2
3 Data relating to the onset of symptoms and initial GP consultation were gathered from
4
5 patients' histories, and therefore relied on patient recollection. However, a previous study
6
7 addressing delay in patients with RA, has highlighted the accuracy of patient recollection by
8
9 comparing patient accounts of their journey to first rheumatology consultation against
10
11 medical records⁴⁰.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests

No competing Interest:

Contributorship

All authors made substantial contributions to the conception or design of the work. The acquisition of data was undertaken by RJS, KR, PK and CD. The analysis and interpretation of data were undertaken by RJS, PN and KR. All authors were involved in drafting the work and revising it critically for important intellectual content. All authors gave final approval of the version published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgements

We would like to thank the staff at the rheumatology departments who collected data for this study.

Funding information

CJ and CDM are part-funded by the NIHR Collaborations for Leadership in Applied Health Research and Care West Midlands. RH is part-funded by North Thames CLAHRC and his contribution was also supported by an NIHR Senior Investigator Award. KS is funded by the NIHR CLAHRC West Midlands initiative. This article presents independent research funded in part by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (funder's reference PB-PG-1208-18114). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Ethical approval information Ethical approval was obtained from South Birmingham Research Ethics Committee (reference no. 10/H1207/98) and all participants gave written informed consent.

Data sharing statement

Data are available upon request from the corresponding author.

Non-author contributors - Delay study syndicate

Sandwell and West Birmingham Hospitals NHS Trust: Biruk Asfaw, Sabrina Kapoor, Kanta

Kumar, Adam Slater & Christopher Buckley

Derby Teaching Hospitals NHS Foundation Trust: Chris Deighton & Alison Booth

Nottingham University Hospitals NHS Trust: Marie-Josophe Pradere, Ira Pande & Ian

Gaywood

St George's University Hospitals NHS Trust: Francesca Leone & Patrick Keily

Lancaster Teaching Hospitals NHS Foundation Trust: Bronwen Evans & Marwan Bukhari

Poole Hospitals NHS Foundation Trust: Julia Taylor, Helena Knowles, & Sarah Westlake

University Hospitals Coventry and Warwickshire NHS Trust: Tanya Potter

Sherwood Forest Hospitals NHS Foundation Trust: Debbie Wilson, Jayne Smith & David

Walsh

King's College Hospitals NHS Foundation Trust: Nyarko Ahwireng, Audu Aderonke & David

Scott

Guy's and St Thomas NHS Foundation Trust: Louise Nel, Naomi Hare & Andrew Cope

North Bristol NHS Trust: Julie Taylor, Wendy Wilmott & Paul Creamer

West Hertfordshire Hospitals NHS Trust: Lynn Currie, Adam Young & Karen Markwell

Lewisham and Greenwich NHS Trust: Louise Pollard & Debbie Johnson

Royal Surrey Country NHS Foundation Trust: Stephanie Allen & Raad Makadsi

Hampshire Hospitals NHS Foundations Trust: Peter Prouse & Janet Cushnaghan

University Hospitals of Leicester NHS Trust: Jessy Sabu & Moorthy Arumugam

County Durham and Darlington NHS Foundation Trust: Matt Bridges & Pam Race

Weston Area Health NHS Trust: Dawn Symonds & Matt Bridges

University Hospitals Birmingham NHS Foundation Trust: Jackie Cobb, Andrew Filer, Simon

Bowman & Paresh Jobanputra

Royal Wolverhampton Hospital NHS Trust (at the time of recruitment the hospital from which patients were recruited was within the Mid Staffordshire NHS Foundation Trust) :

Julie Edwards & Tom Sheeran

East Kent Hospitals University NHS Foundation Trust: Caroline Crowley & Imad Jassim

University Hospitals of the North Midlands NHS Trust: Julie Gray & Jon Packham

1
2
3 NHS Fife: Paul Allcoat & Helen Harris

4 Yeovil District Hospital NHS Foundation Trust: Rebecca Rowland & Sally Knights

5
6 Northumbria Healthcare NHS Foundation Trust AND The Newcastle Upon Tyne Hospitals

7
8 NHS Foundation Trust: Peta Heslop, Sandra Robinson, David Walker, Heather Russell &

9
10 Sheryl Mitchell

11
12 Chesterfield Royal Hospital NHS Foundation Trust: Heather Cripps & Kevin Fairburn

13
14 Lancashire Teaching Hospitals NHS Foundation Trust AND East Lancashire Hospital NHS

15
16 Trust: Sue Cotterell, Gillian Welch, Ayesha Madan & Lee Suan Teh

17
18 Cambridge University Hospitals NHS Foundation Trust: Lucy Winstanley & Shweta Bhagat

19
20 The Dudley Group NHS Foundation Trust: Lucy Kadiki, Chitra Ramful & Ravinder Sandhu

21
22 Royal Cornwall Hospitals NHS Trust: Amanda Datson, & Anthony Woolf

Reference List

- (1) Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2012; 72(8):1315-1320.
- (2) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002; 41(7):793-800.
- (3) National Audit Office. Services for people with rheumatoid arthritis. National Audit Office . 2009. London, The Stationery Office. 24-1-2013.
Ref Type: Report
- (4) van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. *Ann Rheum Dis* 2015; 74(5):806-812.
- (5) Feldman DE, Bernatsky S, Houde M, Beauchamp ME, Abrahamowicz M. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? *Rheumatology (Oxford)* 2013; 52(3):452-459.
- (6) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906-914.
- (7) Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2006; 20(5):849-863.
- (8) Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? *Ann Rheum Dis* 2015; 74(5):793-794.
- (9) Scott DL, Hunter J, Deighton C, Scott DG, Isenberg D. Treatment of rheumatoid arthritis is good medicine. *BMJ* 2011; 343:d6962.
- (10) van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum* 2010; 62(12):3537-3546.
- (11) Feldman DE, Bernatsky S, Haggerty J, Leffondre K, Tousignant P, Roy Y et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2007; 57(8):1419-1425.
- (12) Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009; 48(1):57-60.

- 1
- 2
- 3 (13) Kumar K, Daley E, Carruthers DM, Situnayake D, Gordon C, Grindulis K et al. Delay in
- 4 presentation to primary care physicians is the main reason why patients with rheumatoid
- 5 arthritis are seen late by rheumatologists. *Rheumatology (Oxford)* 2007; 46(9):1438-1440.
- 6
- 7 (14) Stack RJ, Simons G, Kumar K, Mallen CD, Raza K. Patient delays in seeking help at the onset
- 8 of rheumatoid arthritis: the problem, its causes and potential solutions. *Aging Health* 2013;
- 9 9(4):425-435.
- 10
- 11 (15) Oliver S, Bosworth A, Airoidi M, Bunyan H, Callum A, Dixon J et al. Exploring the healthcare
- 12 journey of patients with rheumatoid arthritis: a mapping project - implications for practice.
- 13 *Musculoskeletal Care* 2008; 6(4):247-266.
- 14
- 15 (16) Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, Hazes JM et al. A systematic
- 16 literature review of strategies promoting early referral and reducing delays in the diagnosis
- 17 and management of inflammatory arthritis. *Ann Rheum Dis* 2012; 27(1):13-22.
- 18
- 19 (17) Van der Elst K, De CD, Vecoven E, Arat S, Meyfroidt S, Joly J et al. Are illness perception and
- 20 coping style associated with the delay between symptom onset and the first general
- 21 practitioner consultation in early rheumatoid arthritis management? An exploratory study
- 22 within the CareRA trial. *Scand J Rheumatol* 2015;1-8.
- 23
- 24 (18) Stack RJ, Llewellyn Z, Deighton C, Kiely P, Mallen CD, Raza K. General practitioners'
- 25 perspectives on campaigns to promote rapid help-seeking behaviour at the onset of
- 26 rheumatoid arthritis. *Scand J Prim Health Care* 2014; 32(1):37-43.
- 27
- 28 (19) Stack RJ, Shani M, Mallen CD, Raza K. Symptom complexes at the earliest phases of
- 29 rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013;
- 30 65(12):1916-1926.
- 31
- 32 (20) De CD, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed analysis
- 33 of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. *Scand*
- 34 *J Rheumatol* 2014; 43(1):1-8.
- 35
- 36 (21) van Nies JA, Brouwer E, de Rooy DP, van Gaalen FA, Huizinga TW, Posthumus MD et al.
- 37 Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. *Ann*
- 38 *Rheum Dis* 2013; 72(8):1302-1307.
- 39
- 40 (22) Zafar S, Badsha H, Mofti A, Delosantos A, Altares J, Matudio G et al. Efforts to increase public
- 41 awareness may result in more timely diagnosis of rheumatoid arthritis. *J Clin Rheumatol*
- 42 2012; 18(6):279-282.
- 43
- 44 (23) Nanji JA, Choi M, Ferrari R, Lyddell C, Russell AS. Time to consultation and disease-modifying
- 45 antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta
- 46 perspective. *J Rheumatol* 2012; 39(4):707-711.
- 47
- 48 (24) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III et al. 2010 rheumatoid
- 49 arthritis classification criteria: an American College of Rheumatology/European League
- 50 Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010; 69(9):1580-1588.
- 51
- 52 (25) van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al.
- 53 Validation of a prediction rule for disease outcome in patients with recent-onset
- 54 undifferentiated arthritis: moving toward individualized treatment decision-making. *Arthritis*
- 55 *Rheum* 2008; 58(8):2241-2247.
- 56
- 57
- 58
- 59
- 60

- 1
2
3 (26) Midas. GeoConvert. <http://geoconvert.mimas.ac.uk>. 2010.
4 Ref Type: Online Source
5
6 (27) IBM SPSS Statistics for Windows [Armonk, NY: IBM Corp; 2015.
7
8 (28) Stack RJ, Mallen CD, Deighton C, Kiely P, Shaw KL, Booth A et al. The development and initial
9 validation of a questionnaire to measure help-seeking behaviour in patients with new onset
10 rheumatoid arthritis. *Health Expect* 2014; Jun(3):1-10.
11
12 (29) Puchner R, Janetschko R, Kaiser W, Linkesch M, Steininger M, Termetsberger R et al. Efficacy
13 and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort
14 Study. *Journal of Rheumatology* 2016; 43(6):1130-1135.
15
16 (30) van Nies JA, Brouwer E, van Gaalen FA, Allaart CF, Huizinga TW, Posthumus MD et al.
17 Improved early identification of arthritis: evaluating the efficacy of Early Arthritis
18 Recognition Clinics. *Ann Rheum Dis* 2012; 72(8):1295-301.
19
20 (31) Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in
21 breast cancer diagnosis by race, socioeconomic status, age and year. *Br J Cancer* 1992;
22 65(6):922-926.
23
24 (32) Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast
25 cancer diagnosis in young women by race/ethnicity. *JAMA Surg* 2013; 148(6):516-523.
26
27 (33) Macleod U, Mitchell ED, Burgess C, Macdonald S, Ramirez AJ. Risk factors for delayed
28 presentation and referral of symptomatic cancer: evidence for common cancers. *Br J Cancer*
29 2009; 101 Suppl 2:S92-S101.
30
31 (34) Griffiths B, Situnayake RD, Clark B, Tennant A, Salmon M, Emery P. Racial origin and its effect
32 on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched
33 cross-sectional study. *Rheumatology (Oxford)* 2000; 39(8):857-864.
34
35 (35) Simons G, Mallen CD, Kumar K, Stack RJ, Raza K. A Qualitative Investigation of the Barriers to
36 Help-seeking Among Members of the Public Presented with Symptoms of New-onset
37 Rheumatoid Arthritis. *J Rheumatol* 2015; 42(4):585-592.
38
39 (36) Kumar K, Daley E, Khattak F, Buckley CD, Raza K. The influence of ethnicity on the extent of,
40 and reasons underlying, delay in general practitioner consultation in patients with RA.
41 *Rheumatology (Oxford)* 2010; 49(5):1005-1012.
42
43 (37) Sheppard J, Kumar K, Buckley CD, Shaw KL, Raza K. 'I just thought it was normal aches and
44 pains': a qualitative study of decision-making processes in patients with early rheumatoid
45 arthritis. *Rheumatology (Oxford)* 2008; 47(10):1577-1582.
46
47 (38) Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the
48 onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative
49 literature. *Ann Rheum Dis* 2012; 71(4):493-497.
50
51 (39) Townsend A, Wyke S, Hunt K. Self-managing and managing self: practical and moral
52 dilemmas in accounts of living with chronic illness. *Chronic Illn* 2006; 2(3):185-194.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(40) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. *Scand J Rheumatol* 2014; 43(1):1-8.

For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes
Objectives	3	State specific objectives, including any prespecified hypotheses	Yes
Methods			
Study design	4	Present key elements of study design early in the paper	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Cross-sectional study - Yes
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes
Bias	9	Describe any efforts to address potential sources of bias	Yes
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes
		(b) Describe any methods used to examine subgroups and interactions	Yes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(c) Explain how missing data were addressed

(d) *Cohort study*—If applicable, explain how loss to follow-up was addressed

Case-control study—If applicable, explain how matching of cases and controls was addressed

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

Continued on next page

For peer review only

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Yes
		(b) Give reasons for non-participation at each stage	Yes
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Yes
		(b) Indicate number of participants with missing data for each variable of interest	Yes
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024361.R1
Article Type:	Research
Date Submitted by the Author:	22-Sep-2018
Complete List of Authors:	Stack, Rebecca; Nottingham Trent University , Division of Psychology Nightingale, Peter; Queen Elizabeth Hospital Birmingham, Wellcome Trust Clinical Research Facility Jinks, Clare; Keele University, Arthritis Research UK Primary Care Centre Study Syndicate, DELAY Shaw, Karen; University of Birmingham, Institute of Applied Health Research Herron-Marx, Sandy; Independent Research Consultant Horne, Rob; UCL, UCL School of Pharmacy Deighton, Chris; Derby Teaching Hospitals NHS Foundation Trust Kiely, Patrick ; St George's University Hospitals NHS Foundation Trust Mallen, Christian; Keele University, Arthritis Research UK Primary Care Centre Raza, Karim; University of Birmingham, Institute of Inflammation and Ageing
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Health services research, Rheumatology
Keywords:	RHEUMATOLOGY, access to care, help seeking, health service research, rheumatoid arthritis

SCHOLARONE™
Manuscripts

1
2
3 **Title: Delays between the onset of symptoms and first rheumatology consultation in**
4
5 **patients with rheumatoid arthritis in the UK: an observational study**
6
7

8
9
10 **Authors**

11 Rebecca J Stack^{1,2}, Peter Nightingale³, Clare Jinks⁴, (DELAY study syndicate), Karen Shaw⁵,
12
13 Sandy Herron-Marx⁶, Rob Horne⁷, Chris Deighton⁸, Patrick Kiely⁹, Christian D Mallen⁴ and
14
15 Karim Raza^{1,10}
16
17

18
19
20
21 **Department and Institutions**
22

- 23 1. Institute of Inflammation and Ageing, University of Birmingham, UK.
- 24 2. Division of Psychology, Nottingham Trent University, Nottingham, UK
- 25 26 3. Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation
27 Trust, Birmingham, UK.
- 28 4. Research Institute for Primary Care and Health Sciences, Keele University, UK.
- 29 5. Institute of Applied Health Research, University of Birmingham, UK
- 30 31 6. Independent Research Consultant, Brussels, Belgium.
- 32 33 7. School of Pharmacy, University of London, UK.
- 34 35 8. Department of Rheumatology, Derby Hospitals NHS Foundation Trust, Derby, UK.
- 36 37 9. Department of Rheumatology, St Georges University Hospital NHS Foundation Trust,
38 London, UK.
- 39 40 10. Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust,
41 Birmingham, UK.
- 42 43
- 44 45
- 46 47
- 48 49
- 50 51
- 52 53
- 54 55
- 56 57
- 58 59
- 60

1
2
3 **Corresponding author**
4

5
6 Professor Karim Raza

7
8 Rheumatology Research Group

9
10 Institute of Inflammation and Ageing (IIA)

11
12 University of Birmingham

13
14 Queen Elizabeth Hospital, Birmingham, B15 2WB

15
16 E mail : k.raza@bham.ac.uk
17
18
19
20

21 **Word Count** (excluding title page, abstract, references and tables): 2499
22
23
24
25
26
27

28 **Keywords**
29

30 Rheumatoid arthritis; patient delay; Primary care delay; help-seeking; access to care;
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths of this study.

This study surveyed a large sample of patients with new onset rheumatoid arthritis in the UK to identified delays in access to care.

This study identified that approximately 20% of patients saw a rheumatologist within 12 weeks of symptom onset, and factors associated with slower self-referral and slower GP referral were identified.

Limitations of this study.

Data were collected at the point of diagnosis and information regarding key dates (in particular the onset of symptoms and presentation to primary care) were reliant on patient recall.

This research has identified factors associated with delays, however, further research is needed to identify factors which would accelerate self-referral, GP referral and hospital waiting times for those experiencing early symptoms.

Abstract

Objective: To investigate delays from symptom onset to rheumatology assessment for patients with a new onset of rheumatoid arthritis (RA) or unclassified arthritis.

Methods: Newly presenting adults with either RA or unclassified arthritis were recruited from rheumatology clinics. Data on the length of time between symptom onset and first seeing a GP (patient delay), between first seeing a GP and being referred to a rheumatologist (general practitioner delay) and being seen by a rheumatologist following referral (hospital delay) were captured.

Results: 822 patients participated (563 female, mean age 55 years). The median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4–26.3 weeks). Patients who purchased over the counter medications or used ice/heat packs took longer to seek help than those who did not. In addition, those with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset. The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks). Patients made a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Conclusion: This study identified delays at all levels in the pathway towards assessment by a Rheumatologist. However, delays in primary care were particularly long. Patient delay was driven by the nature of symptom onset. Complex multi-faceted interventions to promote rapid help seeking and to facilitate prompt onward referral from primary care should be developed.

Introduction:

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately 1% of the population.^{1;2} Rheumatoid arthritis is associated with significant morbidity in large part as a consequence of extra-articular co-morbidities associated with systemic inflammation. In the UK it has been estimated that RA costs the NHS around £560 million per year and that additional costs to the economy of sick leave and work-related disability total £1.8 billion per year.³ The first three months following the onset of RA symptoms represents an important therapeutic window.⁴ Treatment during this phase improves long-term clinical outcomes, increasing the proportion of patients whose disease enters remission, reducing RA related joint damage and reducing the eventual need for joint replacement surgery.⁵⁻¹⁰ Therefore, it is vital that patients are seen by Rheumatologists rapidly following the onset of RA symptoms to allow the rapid introduction of disease modifying anti-rheumatic drug treatment. However, despite increased recognition of the benefits of early treatment there remains considerable delay between symptom onset and the initiation of therapy.¹¹⁻¹³ Indeed a report by the UK's National Audit Office (NAO) in 2009 estimated that only 10% of patients with RA were treated within three months of symptom onset. The NAO's modelling suggested significant financial benefits for the broader economy and quality of life benefits for the individual if the proportion of patients treated earlier was increased.³

The patient's pathway to care can be delayed for a number of reasons, including delays on the part of the patient in recognising the significance of the early symptoms of RA.¹⁴⁻¹⁶

1
2
3 Recent research has linked patients' perceptions of RA and coping styles to the length of
4
5 time taken to seek help.¹⁷ Before seeking medical help from a physician, patients may seek
6
7 help from a range of services including complementary therapists, pharmacists and
8
9 telephone and on-line services. However, the use of these services at the onset of
10
11 inflammatory arthritis has not been fully explored. Primary healthcare professionals often
12
13 find the early symptoms of RA difficult to distinguish from those of other rheumatic
14
15 diseases, making timely and appropriate referrals to rheumatologists challenging.^{18;19} There
16
17 may thus be delays in healthcare professionals making a referral to a Rheumatologist and
18
19 also in assessment at the secondary care level, contributing further to the delay in making a
20
21 diagnosis and commencing appropriate therapy.
22
23
24
25
26
27

28 Several studies conducted across a range of countries have shown long delays between the
29
30 onset of symptoms and a patient's first consultation with a rheumatologist.²⁰⁻²³ However,
31
32 data related to lengths of time between the onset of inflammatory musculoskeletal
33
34 symptoms and first seeing a GP, between first seeing a GP and being referred to a
35
36 rheumatologist and being seen by a rheumatologist following referral were not available
37
38 across multiple NHS Trusts in multiple regions of the UK at the time of this study.
39
40
41
42
43

44 **Aim**

45
46 The aim of this study was to investigate the extents of delay in assessment of patients with
47
48 RA and unclassified arthritis. Specifically the study assessed extents of delay at the level of
49
50 the patient in seeking help from the general practitioner, the general practitioner in
51
52 referring to a Rheumatologist and the Rheumatologist in assessing the patient following
53
54 referral. The relationships between extents of delay and clinical and demographic variables
55
56
57
58
59
60

1
2
3 were explored and data captured relating to sources of information, help and advice utilized
4
5 by patients prior to GP consultation.
6
7
8

9 10 **Methods**

11
12 A questionnaire based survey of consecutively presenting patients with a new onset of RA or
13
14 unclassified inflammatory arthritis was undertaken in England and Scotland. Networks such
15
16 as the Early Rheumatoid Arthritis Network²⁴ and the National Institute for Health Research
17
18 Clinical Research Network²⁵ were used identify Rheumatology centres to participate in this
19
20 study. RJS also promoted the study during abstract presentations at British Society for
21
22 Rheumatology meetings.
23
24
25

26
27
28 Data were collected from Rheumatology departments in 34 NHS Trusts. Rheumatology
29
30 departments were secondary care based, although one rheumatology department
31
32 (Sandwell and West Birmingham Hospitals) operated clinics in both hospital and community
33
34 settings. Eligible patients were recruited on their first or second visit to the rheumatology
35
36 department following a primary care referral (data were not collected on the numbers of
37
38 patients whose data were collected at their first visit or at their second visit). Rheumatologists
39
40 were asked to approach consecutively presenting patients who met the eligibility criteria.
41
42
43

44 Eligible patients were newly referred adults (aged ≥ 18 years) with clinically apparent
45
46 synovial swelling of one or more joints who had either a new onset of RA (according to 2010
47
48 ACR / EULAR criteria²⁶) or unclassified arthritis (UA; defined as a failure to fulfil classification
49
50 criteria for another inflammatory rheumatic disease). Patients with UA were recruited, as in
51
52 many cases patients with UA at initial secondary care assessment progress to RA over
53
54
55 time.²⁷
56
57
58
59
60

1
2
3
4
5 Data were collected using two questionnaires (available from the corresponding author on
6
7 request). First, following consent, the recruiting healthcare professional, with the patient
8
9 present, completed a questionnaire that captured data on extents of delays between [1]
10
11 symptom onset and seeing a healthcare professional (from herein referred to as 'patient
12
13 delay', these data was gathered from the patient's account by the recruiting healthcare
14
15 professional), [2] seeing a general practitioner and being referred to a rheumatologist (from
16
17 herein referred to as 'general practitioner e delay', these data was gathered from the
18
19 patient's account by the recruiting healthcare professional), and [3] being referred to a
20
21 rheumatologist and seeing a rheumatologist (from herein referred to as 'hospital delay',
22
23 these data were gathered from referral letters and hospital notes). Data were also gathered
24
25 on [1] demographic variables including the patient's age, gender, education, employment
26
27 status and postcode; deprivation ranks were calculated from postcode data using
28
29 Geoconvert 2010 which produced an Index of Multiple Deprivation (IMD) score,²⁸ [2] clinical
30
31 variables including the mode of symptom onset (palindromic (defined as intermittent
32
33 symptoms) vs. non-palindromic (defined as persistent symptoms)), rapidity of symptom
34
35 onset (acute vs. insidious; an acute onset was typically viewed as an onset of symptoms
36
37 which came on rapidly over 24-48 hours), duration of morning stiffness, swollen and tender
38
39 joint counts, Disease Activity Score 28 (DAS28) and fulfilment of 2010 ACR/EULAR criteria for
40
41 classification of RA²⁶.

42
43
44 In addition, via a separate questionnaire that patients completed by themselves, patients
45
46 provided data on actions taken in relation to their symptoms prior to seeking help from
47
48 primary care . The variables captured were informed by previous qualitative research,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 including patient interviews and interviews with healthcare professionals. In addition, we
4
5 had input from Patient Research Partners and the questions asked were validated and
6
7 assessed for reliability²⁹.
8
9

10 11 12 **Patient and Public Involvement**

13
14 Patient and public involvement was an important element of this study. Patient
15
16 representatives from Sandwell and West Birmingham Hospitals NHS Trust were involved in
17
18 the study design, advised on the content of patient facing materials including participant
19
20 information sheets and consent forms and the content of questionnaires including
21
22 questions related to actions taken by patients prior to consulting their GPs. Patients were
23
24 members of the Project Management Group reviewing study recruitment and supporting
25
26 the Group in developing approaches to ensure that recruitment proceeded to time and
27
28 target
29
30
31
32
33
34
35

36 **Analysis**

37
38 To ensure that the data met parametric assumptions, the distribution and levels of
39
40 multicollinearity between variables were checked. Data on patient delays, general
41
42 practitioner delays and hospital delays were not normally distributed, therefore, log values
43
44 of these delay data were created to generate normally distributed variables.
45
46
47

48
49 For each of the outcomes patient delay, general practitioner delay and hospital delay a
50
51 general linear model was used with main effects and two-way interactions for the following
52
53 explanatory variables: gender, ethnicity, IMD score, age, education, employment status,
54
55 mode of onset, rapidity of onset, patient reported family history of RA and RA vs. UA. For
56
57
58
59

each outcome any two-way interactions which were not significant were removed in a backwards stepwise fashion, with the pairings with the highest p values being removed first. All main effects were retained, so that the final model for each outcome included all ten explanatory variables and any significant two-way interactions ($p < 0.01$). All significant main effects and interactions are reported in the Results section.

Results

1. Participant characteristics

Data were collected from 856 patients between 2011 and 2014. Patients were withdrawn from the study due to incomplete data (21 cases) and ineligibility (13 cases in whom there was no clinical synovitis reported at recruitment). Data were thus analysed from 822 patients of whom 68.5% were female with a mean age of 55 years. Characteristics of patients are presented in table 1.

Table 1: Demographic and disease related characteristics of patients. Data are presented as either percentage (number) or median (IQR) as appropriate. Tender joint count is out of 42 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 hip, 2 knee, 2 ankle, 10 MTP). Swollen joint count is out of 40 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 knee, 2 ankle, 10 MTP).

Female	68.5% (563)
Age, years	57 (45-67)
Diagnosis of RA	73% (603)
Ethnicity: Black British	6.0% (49)

South Asian	7.7% (63)
White British	84.9% (698)
Other	1.5% (12)
Self-reported family history of RA	34.9% (287)
Palindromic onset	42.8% (352)
Acute onset	35.9% (295)
Duration of morning stiffness, minutes	60 (10-120)
DAS28	4.88 (3.98 -5.80)
HAQ	1.13 (0.50-1.73)
Tender joint count	9 (4-18)
Swollen joint count	5 (2-10)

2. Intervals between symptom onset and first rheumatology consultation

Overall the median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1 – 66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks). The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks) with patients making a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

1
2
3 Patients with a palindromic symptom onset had a significantly longer patient delay than
4
5 those with a non-palindromic onset (9.3 weeks (IQR 2-43 weeks) vs 4.3 weeks (IQR 1-17
6
7 weeks); $p < 0.001$, t-test). Furthermore, those with an acute symptom onset had significantly
8
9 shorter patient delays than those with an insidious symptoms onset (2.4 weeks (IQR 1 - 6.6
10
11 weeks) vs 11.1 weeks (IQR 4-44 weeks; $p < 0.001$, t-test).
12
13

14 15 16 17 *Resources used before seeking help from primary care*

18
19
20 Patients reported taking a range of actions in relation to their symptoms before seeking help
21
22 from their GP and in some cases these actions were associated with longer delays in GP
23
24 consultation (see table 2). Most often patients reported purchasing tablets from 'the
25
26 chemist', although only a small proportion actually reported speaking to a pharmacist.
27
28 Other actions reported by patients included applying heat or cold packs to joints or buying
29
30 joint supports.
31
32
33
34
35
36
37

38 **Table 2.** *Actions taken by patients with inflammatory arthritis before seeking help from their*
39
40 *GP with comparison made for patient delay between those who did and did not undertake*
41
42 *this action using independent t-tests; * P value for comparison of those who did and did not*
43
44 *undertake this action.*
45
46
47

Actions taken before seeking help from GP	% (number) of participants undertaking this action	Median (IQR) patient delay in weeks for those undertaking	Median (IQR) patient delay in weeks for those not undertaking	P value

		this action	this action	
Bought tablets from the chemist	51.1% (273 out of 534)	6.9 (2-30.7)	4.7 (1.4-23)	p=0.036
Used an ice or heat pack on joint	47.8% (254 out of 531)	7.6 (2-30.3)	4.9 (2-26.1)	p=0.045
Took baths	47.4% (251 out of 529)	6.3 (2-30.4)	5.6 (2-26.1)	p=0.473
Bought joint supports (splints, tubi-grips etc)	37.4% (198 out of 529)	4.4 (2.1-18.6)	5.1 (2-26.9)	p=0.362
Used alternative therapies	25.2% (134 out of 531)	8.3 (2-42.1)	5.3 (2-26.3)	p=0.020
Bought products from a health shop	19.0% (101 out of 532)	5.9 (2-36.3)	5.9 (2-26)	p=0.182
Modified diet	14.4% (76 out of 529)	6 (2.1-35.3)	6.1(2-26.3)	p= 0.183
Used prayer or sought spiritual guidance	8.4% (45 out of 534)	4.4 (2.1-18.6)	6.3 (2-26.9)	p=0.941
Spoke to a pharmacist	7.9% (41 out of 521)	5.9 (2-38.1)	5.9 (2-26.3)	p=0.544

1
2
3
4
5
6 Thirty-seven percent of patients reported looking on the internet (for example visiting the
7
8 NHS direct website, BUPA website, Arthritis Research UK website and searching for
9
10 information using search engines such as Google). Patients also reported seeking support via
11
12 a telephone helpline; 5.7% described calling the NHS direct helpline or another telephone
13
14 health advice service. 3.7% sought help in the workplace (e.g. from an occupational nurse),
15
16 2% of patients went directly to the Accident and Emergency Department and 1% attended
17
18 an NHS walk-in centre.
19
20
21
22
23
24
25

26 **Multivariate analysis: Patient delay**

27
28
29 The interaction model showed main effects for mode of onset (palindromic vs. non-
30
31 palindromic; $F=26.65$, $P<0.01$) and rapidity of onset (acute vs. insidious; $F= 65.36$, $P<0.01$).
32
33 An interaction was found between palindromic onset and gender ($F=45.658$, $P<0.01$); men
34
35 with a palindromic onset waited significantly longer before seeking help.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Multivariate analysis: General practitioner delay

A main effect was found for ethnicity ($F=6.26$, $P<0.01$). Significant differences in general practitioner delay were found between White British and South Asian patients (6.2 weeks (IQR 2-18.6) vs 22 weeks (IQR 6.5-39.8); $P<0.001$) and between White British and Black British patients (6.2 weeks (IQR 2-18.6) vs 11.1 weeks (IQR 4.3-21.7); $P<0.001$). No significant difference was found between South Asian and Black British patients ($P=1.000$).

A main effect was also found for family history ($F=5.89$, $P<0.01$); the median general practitioner delay for those with a self-reported family history of RA was 9 weeks (IQR 2.4-25.7), while general practitioner delay for those with no family history was 6.3 weeks (IQR 2.3-19). Interactions at a statistically significant level (<0.01) were not found.

Multivariate analysis: Hospital delay

The original model included main effects and two-way interactions for the following explanatory variables: gender, ethnicity, IMD score, age, education, employment status, mode of onset, rapidity of onset, family onset and RA vs. UA. None of the main effects or interactions (when removed backwards) were significant in predicting the delay between referral and being seen in secondary care.

Discussion

International guidelines recommend that the treatment of RA should begin as soon as possible after the onset of symptoms, ideally aiming to capture patients within the first 3 months following symptom onset. However, this large UK study of delays in access to care for RA patients found that the median patient delay in seeking help at the onset of symptoms was 5.4 weeks, while the median delay between seeing a healthcare professional and being referred was 6.9 weeks. Our study highlights that only 20% of patients were seen within the first 3 months of symptom onset. This appears to be lower than the rate reported in other European countries for example a recent study in Austria reported that 38% of patients were seen within the first 3 months³⁰. The present study also found an average delay of 4.7 weeks from referral until the patient was seen by a rheumatologist, similar to figures reported in the NAO report³. Unlike our previous study conducted at a single centre in the UK where patient delay accounted for the largest element of delay,¹³ we found that GP delay was the largest contributor to overall delay; patient delay was less than we had previously reported in our single centre study.

This research highlights that delays in primary care are long, and a major contributor to overall delays between symptom onset and the first rheumatology visit. General practitioners are faced with a number of barriers to identifying patients with newly presenting RA including the often non-specific nature of symptoms at the earliest stages of RA.¹⁸ Research is underway to define symptom complexes most predictive of RA development in patients with newly presenting musculoskeletal symptoms. For example, a questionnaire has been developed and validated to capture such symptoms in patients

1
2
3 presenting with joint symptoms which by history are suggestive of an underlying
4
5 inflammatory cause³¹ and data are currently being collected from such patients in secondary
6
7 care based longitudinal observational cohort studies to identify symptoms that may predict
8
9 RA development. Furthermore an assessment of primary care databases has identified a
10
11 range of symptoms including hand related joint symptoms, morning stiffness and carpal
12
13 tunnel syndrome type symptoms as being ones with which patients frequently present to
14
15 the GP prior to the point at which the GP refers the patient to a Rheumatologist or records a
16
17 diagnosis of RA³² It is likely that a combination of education, and evidence based referral
18
19 algorithms, will be needed to ensure that suspected cases are referred early. For example,
20
21 in Fife, Scotland GPs did not have access to rheumatoid factor testing during the course of
22
23 our study, and used guidelines with pictorial representations to help identify early synovitis
24
25 (personal communication Dr Helen Harris). Fife was a participating centre in this study, and
26
27 was found to have the lowest GP referral time of all centres surveyed. Furthermore,
28
29 facilitating access to secondary care, for example through the establishment of rapid
30
31 assessment clinics whose main aim is to identify whether the patient does or does not have
32
33 synovitis have been shown to significantly reduce delays in the assessment of patients.³³ A
34
35 limitation of our research is that the study was not able to assess regional differences across
36
37 NHS Trusts. A study comparing delays and referral patterns between hospitals with local
38
39 policies and practices which may influence the time between onset and first consultation
40
41 would be useful and an international study would be particularly helpful.
42
43
44
45
46
47
48
49
50

51 A number of factors were found to influence GP delay including ethnicity. Studies in the field
52
53 of oncology have also found that people from ethnic minority backgrounds face longer GP
54
55 delays,^{34;35} In the context of RA it is possible that the early symptomatology of patients from
56
57
58
59
60

1
2
3 ethnic minority backgrounds is different from, and less typical of RA than that of, patients of
4
5 white British background, thus making recognition more challenging for GPs. Data certainly
6
7 exist that the clinical phenotype of established RA differs in patients of South Asian origin
8
9 compared with patients of White British origin,³⁶ though data relating the clinical
10
11 presentations of RA in these groups are lacking. Furthermore, it is unclear why a self-
12
13 reported family history of RA would be associated with longer delays although it is
14
15 important to recognise that GPs may not have elicited this information from the patient.³⁷
16
17 Qualitative approaches may be helpful to address some of these issues in the future.
18
19
20
21
22

23 Previous qualitative studies and a meta-synthesis have identified barriers to help seeking at
24
25 the onset of RA.³⁷⁻⁴³ The present study identifies that before seeking formal medical
26
27 attention, people experiencing the early symptoms of RA seek information and help from a
28
29 number of alternative sources and often self-medicate. We identified that buying tablets
30
31 from a pharmacy, and using heat or ice on joints was significantly associated with longer
32
33 patient delays. This finding highlights that some self-management behaviours, particularly
34
35 those linked to accessing pharmacy services can negatively impact on the time it takes to
36
37 seek help; this needs further exploration. Factors previously suggested to be associated
38
39 with delays in GP consultation included an insidious onset of mild symptoms and a lack of
40
41 knowledge about RA, personal susceptibility to RA and the availability of treatments to slow
42
43 disease progression. In our national sample 64.1% of people describe an insidious onset of
44
45 RA, and 42.8% describe a palindromic onset of RA. Therefore, majority large proportion of
46
47 patients surveyed experienced a slow and / or intermittent onset of their inflammatory joint
48
49 symptoms. Our quantitative data are thus consistent with results from qualitative studies,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 demonstrating that the mode and rapidity of onset of symptoms is significantly associated
4
5 with patient delays.
6

7 This study has a number of limitations. Firstly, the interval between first consultation with a
8
9 Rheumatologist and initiation of disease modifying anti-rheumatic drug (DMARD) treatment
10
11 was not measured. Any additional delay in commencing DMARD treatment will negatively
12
13 impact the patient and variables associated with delays at this level should be assessed in
14
15 future studies. Secondly, during the course of this study a number of guidelines related to
16
17 RA management were published which may have influenced practice, and patterns of
18
19 referral. We were not able to explore the relationships between the availability / local
20
21 adoption of guidelines and delays in the assessment of patients. Future investigation should
22
23 assess the impact of policy changes on patterns of help-seeking, referral and assessment.
24
25 Thirdly, the rheumatology centres participating in this study were self-selecting, therefore,
26
27 there may be biases in the characteristics of the rheumatology centres which participated in
28
29 this study. For example, the participating rheumatology units may have had a particular
30
31 interest in early arthritis. Only a study which recruited consecutive patients from all
32
33 rheumatology units across the UK would be able to provide a truly national picture.
34
35 Fourthly, whilst we were able to document the length of delay at a primary care level there
36
37 were important variables which may have influenced this delay which we did not record and
38
39 so were unable to explore. For example it would have been helpful have access to results
40
41 tests performed in primary care to assess whether levels of inflammatory markers or RA
42
43 related autoantibodies measured in primary care influenced the rapidity of referral from
44
45 primary care. Indeed a recent quantitative survey of GPs' anticipated actions in primary care
46
47 when dealing with patients with suspected RA suggest that results of these tests may
48
49 influence GP behaviours⁴⁴. Future research should address this. Similarly, a number of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 secondary care related variables may have influenced the extent of secondary care delay
4
5 including the number of rheumatologists at each Trust, whether a dedicated early arthritis
6
7 clinic was in place and approaches taken to the triage of referrals. Data relating to these
8
9 variables were not collected though future work addressing issues of delay should address
10
11 these important issues. Fifthly, data relating to the dates of onset of symptoms and initial
12
13 GP consultation were gathered from patients' histories, and therefore relied on patient
14
15 recollection with a possible associated error. However, a previous study addressing delays in
16
17 the assessment of patients with RA, compared patient accounts of their journeys to first
18
19 rheumatology consultation against medical records and highlighted the accuracy of patient
20
21 recollection in relation to dates found to be documented in primary care records⁴⁵. This, to
22
23 some extent, validates our approach of using patient memory to define the dates of
24
25 symptom onset and initial GP presentation. An alternative approach would be a
26
27 longitudinal observational study in the general population to track the development of
28
29 symptoms and the relationship between that and GP consultation, GP referral and
30
31 secondary care assessment. A challenge with this approach is the low incidence of RA and
32
33 thus the requirement for a very large sample size. One could potentially enrich the
34
35 population for RA risk by, for example, following individuals who are at increased risk of RA
36
37 (e.g. the first degree relatives of patients with RA). However, one of the challenges with this
38
39 strategy is that simply being involved in such a study may influence subsequent patient and
40
41 GP behaviour.
42
43
44
45
46
47
48
49
50

51 Whilst delays in primary care are the largest contributor to overall delay, patient delay and
52
53 hospital delay represent important components. This study found that the nature of
54
55 symptoms onset influenced how quickly patients with RA sought help, suggesting that those
56
57
58
59
60

1
2
3 with an acute onset of persistent symptoms seek help faster than those with insidious and
4
5 palindromic onsets. Interventions to encourage rapid help seeking should consider
6
7 highlighting the frequently insidious onset of RA to members of the public stressing that
8
9 help should be sought even when symptoms are mild. However, even those with a rapid
10
11 onset of persistent symptoms often delayed for prolonged periods before seeking help. We
12
13 have previously shown that members of the public view musculoskeletal symptoms, even
14
15 those with clear inflammatory features, as less worrisome and less requiring rapid
16
17 assessment as compared with symptoms of other common diseases such as ischaemic type
18
19 chest pain or bowel disturbance with associated rectal blood loss⁴⁶. Enhanced public
20
21 education to highlight the significance of inflammatory type musculoskeletal symptoms is
22
23 thus likely to be needed. Interventions at multiple levels, including at the levels of the
24
25 public, the services which members of the public consult after the onset of symptoms (e.g.
26
27 pharmacies), primary care and secondary care will be needed to reduce overall delays in
28
29 access to appropriate specialists.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests

No competing Interest:

Contributorship

RJS, CJ, SHM, CDM, KS, RH, CD, PK and KR made substantial contributions to the conception or design of the work. The acquisition of data was undertaken by RJS, KR, PK and CD. RJS, CJ and SHM facilitated patient and public involvement in the design, delivery and interpretation of this study. The analysis and interpretation of data were undertaken by RJS, PN and KR. RJS, PN, CJ, SHM, CDM, KS, RH, CD, PK and KR were involved in drafting the work and revising it critically for important intellectual content. RJS, CJ, SHM, CDM, KS, RH, CD, PK and KR gave final approval of the version published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgements

We would like to thank the staff at the rheumatology departments who collected data for this study. We would also like to thank patient research partners at Sandwell and West Birmingham Hospitals NHS Trust for their help and support with this study.

Funding information

This article presents independent research funded in part by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (funder's reference PB-PG-1208-18114). CDM is funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research and a NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). CJ is part-funded by the NIHR Collaborations for Leadership in Applied Health Research and Care West Midlands. RH is part-funded by North Thames CLAHRC and his contribution was also supported by an NIHR Senior Investigator Award. KS is funded by the NIHR CLAHRC West Midlands initiative. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

1
2
3 **Ethical approval information** Ethical approval was obtained from South Birmingham
4 Research Ethics Committee (reference no. 10/H1207/98) and all participants gave written
5 informed consent.
6
7

8
9
10 **Data sharing statement**

11 Data are available upon request from the corresponding author.
12
13

14
15 **Non-author contributors - Delay study syndicate**

16
17
18 Sandwell and West Birmingham Hospitals NHS Trust: Biruk Asfaw, Sabrina Kapoor, Kanta
19 Kumar, Adam Slater & Christopher Buckley

20
21 Derby Teaching Hospitals NHS Foundation Trust: Chris Deighton & Alison Booth

22
23 Nottingham University Hospitals NHS Trust: Marie-Josephe Pradere, Ira Pande & Ian
24 Gaywood

25
26 St George's University Hospitals NHS Trust: Francesca Leone & Patrick Keily

27
28 Lancaster Teaching Hospitals NHS Foundation Trust: Bronwen Evans & Marwan Bukhari

29
30 Poole Hospitals NHS Foundation Trust: Julia Taylor, Helena Knowles, & Sarah Westlake

31
32 University Hospitals Coventry and Warwickshire NHS Trust: Tanya Potter

33
34 Sherwood Forest Hospitals NHS Foundation Trust: Debbie Wilson, Jayne Smith & David
35 Walsh

36
37 King's College Hospitals NHS Foundation Trust: Nyarko Ahwireng, Audu Aderonke & David
38 Scott

39
40 Guy's and St Thomas NHS Foundation Trust: Louise Nel, Naomi Hare & Andrew Cope

41
42 North Bristol NHS Trust: Julie Taylor, Wendy Wilmott & Paul Creamer

43
44 West Hertfordshire Hospitals NHS Trust: Lynn Currie, Adam Young & Karen Markwell

45
46 Lewisham and Greenwich NHS Trust: Louise Pollard & Debbie Johnson

47
48 Royal Surrey Country NHS Foundation Trust: Stephanie Allen & Raad Makadsi

49
50 Hampshire Hospitals NHS Foundations Trust: Peter Prouse & Janet Cushnaghan

51
52 University Hospitals of Leicester NHS Trust: Jessy Sabu & Moorthy Arumugam

53
54 County Durham and Darlington NHS Foundation Trust: Matt Bridges & Pam Race

55
56 Weston Area Health NHS Trust: Dawn Symonds & Matt Bridges
57
58
59
60

1
2
3 University Hospitals Birmingham NHS Foundation Trust: Jackie Cobb, Andrew Filer, Simon
4 Bowman & Paresh Jobanputra

5
6 Royal Wolverhampton Hospital NHS Trust (at the time of recruitment the hospital from
7 which patients were recruited was within the Mid Staffordshire NHS Foundation Trust) :

8
9 Julie Edwards & Tom Sheeran

10
11 East Kent Hospitals University NHS Foundation Trust: Caroline Crowley & Imad Jassim

12
13 University Hospitals of the North Midlands NHS Trust: Julie Gray & Jon Packham

14
15 NHS Fife: Paul Allcoat & Helen Harris

16
17 Yeovil District Hospital NHS Foundation Trust: Rebecca Rowland & Sally Knights

18
19 Northumbria Healthcare NHS Foundation Trust AND The Newcastle Upon Tyne Hospitals

20
21 NHS Foundation Trust: Peta Heslop, Sandra Robinson, David Walker, Heather Russell &
22 Sheryl Mitchell

23
24 Chesterfield Royal Hospital NHS Foundation Trust: Heather Cripps & Kevin Fairburn

25
26 Lancashire Teaching Hospitals NHS Foundation Trust AND East Lancashire Hospital NHS
27 Trust: Sue Cotterell, Gillian Welch, Ayesha Madan & Lee Suan Teh

28
29 Cambridge University Hospitals NHS Foundation Trust: Lucy Winstanley & Shweta Bhagat

30
31 The Dudley Group NHS Foundation Trust: Lucy Kadiki, Chitra Ramful & Ravinder Sandhu

32
33 Royal Cornwall Hospitals NHS Trust: Amanda Datson, & Anthony Woolf
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

- (1) Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2012; 72(8):1315-1320.
- (2) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002; 41(7):793-800.
- (3) National Audit Office. Services for people with rheumatoid arthritis. National Audit Office . 2009. London, The Stationery Office. 24-1-2013.
- (4) van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. *Ann Rheum Dis* 2015; 74(5):806-812.
- (5) Feldman DE, Bernatsky S, Houde M, Beauchamp ME, Abrahamowicz M. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? *Rheumatology (Oxford)* 2013; 52(3):452-459.
- (6) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906-914.
- (7) Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2006; 20(5):849-863.
- (8) Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? *Ann Rheum Dis* 2015; 74(5):793-794.
- (9) Scott DL, Hunter J, Deighton C, Scott DG, Isenberg D. Treatment of rheumatoid arthritis is good medicine. *BMJ* 2011; 343:d6962.
- (10) van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum* 2010; 62(12):3537-3546.
- (11) Feldman DE, Bernatsky S, Haggerty J, Leffondre K, Tousignant P, Roy Y et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2007; 57(8):1419-1425.
- (12) Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009; 48(1):57-60.
- (13) Kumar K, Daley E, Carruthers DM, Situnayake D, Gordon C, Grindulis K et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. *Rheumatology (Oxford)* 2007; 46(9):1438-1440.

- 1
2
3 (14) Stack RJ, Simons G, Kumar K, Mallen CD, Raza K. Patient delays in seeking help at the onset
4 of rheumatoid arthritis: the problem, its causes and potential solutions. *Aging Health* 2013;
5 9(4):425-435.
6
7 (15) Oliver S, Bosworth A, Airoidi M, Bunyan H, Callum A, Dixon J et al. Exploring the healthcare
8 journey of patients with rheumatoid arthritis: a mapping project - implications for practice.
9 *Musculoskeletal Care* 2008; 6(4):247-266.
10
11 (16) Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, Hazes JM et al. A systematic
12 literature review of strategies promoting early referral and reducing delays in the diagnosis
13 and management of inflammatory arthritis. *Ann Rheum Dis* 2012; 27(1):13-22.
14
15 (17) Van der Elst K, De CD, Vecoven E, Arat S, Meyfroidt S, Joly J et al. Are illness perception and
16 coping style associated with the delay between symptom onset and the first general
17 practitioner consultation in early rheumatoid arthritis management? An exploratory study
18 within the CareRA trial. *Scand J Rheumatol* 2015;1-8.
19
20 (18) Stack RJ, Llewellyn Z, Deighton C, Kiely P, Mallen CD, Raza K. General practitioners'
21 perspectives on campaigns to promote rapid help-seeking behaviour at the onset of
22 rheumatoid arthritis. *Scand J Prim Health Care* 2014; 32(1):37-43.
23
24 (19) Stack RJ, Shani M, Mallen CD, Raza K. Symptom complexes at the earliest phases of
25 rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013;
26 65(12):1916-1926.
27
28 (20) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed
29 analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis
30 patients. *Scand J Rheumatol* 2014; 43(1):1-8
31
32 (21) van Nies JA, Brouwer E, de Rooy DP, van Gaalen FA, Huizinga TW, Posthumus MD et al.
33 Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. *Ann*
34 *Rheum Dis* 2013; 72(8):1302-1307.
35
36 (22) Zafar S, Badsha H, Mofti A, Delosantos A, Altares J, Matudio G et al. Efforts to increase public
37 awareness may result in more timely diagnosis of rheumatoid arthritis. *J Clin Rheumatol*
38 2012; 18(6):279-282.
39
40 (23) Nanji JA, Choi M, Ferrari R, Lyddell C, Russell AS. Time to consultation and disease-modifying
41 antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta
42 perspective. *J Rheumatol* 2012; 39(4):707-711.
43
44 (24) Garwood W. The Early Rheumatoid Arthritis Network (ERAN). *Musculoskeletal care*. 2004
45 Nov;2(4):240-4.
46
47 (25) The National Institute for Health Research Clinical Research Network.
48 <https://www.nihr.ac.uk/about-us/how-we-are-managed/managing-centres/crn/> (accessed
49 16th August 2018)
50
51 (26) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III et al. 2010 rheumatoid
52 arthritis classification criteria: an American College of Rheumatology/European League
53 Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010; 69(9):1580-1588.
54
55
56
57
58
59

- 1
2
3 (27) van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al.
4 Validation of a prediction rule for disease outcome in patients with recent-onset
5 undifferentiated arthritis: moving toward individualized treatment decision-making. *Arthritis*
6 *Rheum* 2008; 58(8):2241-2247.
7
- 8 (28) Midas. GeoConvert. <http://geoconvert.mimas.ac.uk>. 2010.
9
10
- 11 (29) Stack RJ, Mallen CD, Deighton C, Kiely P, Shaw KL, Booth A et al. The development and initial
12 validation of a questionnaire to measure help-seeking behaviour in patients with new onset
13 rheumatoid arthritis. *Health Expect* 2014; Jun(3):1-10.
14
- 15 (30) Puchner R, Janetschko R, Kaiser W, Linkesch M, Steininger M, Termetsberger R et al. Efficacy
16 and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort
17 Study. *Journal of Rheumatology* 2016; 43(6):1130-1135.
18
- 19 (31) van Beers-Tas MH, ter Wee MM, van Tuyl LH, Maat B, Hoogland W, Hensvold AH, Catrina AI,
20 Mosor E, Stamm TA, Finckh A, Courvoisier DS. Initial validation and results of the Symptoms
21 in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project. *RMD*
22 open. 2018 May 1;4(1):e000641.
23
- 24 (32) Muller S, Hider S, Machin A, Stack R, Hayward RA, Raza K, Mallen C. Searching for a
25 prodrome for rheumatoid arthritis in the primary care record: A case-control study in the
26 clinical practice research datalink. In Seminars in arthritis and rheumatism 2018 Jun 23. WB
27 Saunders.
28
- 29 (33) van Nies JA, Brouwer E, van Gaalen FA, Allaart CF, Huizinga TW, Posthumus MD et al.
30 Improved early identification of arthritis: evaluating the efficacy of Early Arthritis
31 Recognition Clinics. *Ann Rheum Dis* 2012; 72(8):1295-301.
32
- 33 (34) Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in
34 breast cancer diagnosis by race, socioeconomic status, age and year. *Br J Cancer* 1992;
35 65(6):922-926.
36
- 37 (35) Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast
38 cancer diagnosis in young women by race/ethnicity. *JAMA Surg* 2013; 148(6):516-523.
39
- 40 (36) Griffiths B, Situnayake RD, Clark B, Tennant A, Salmon M, Emery P. Racial origin and its effect
41 on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched
42 cross-sectional study. *Rheumatology (Oxford)* 2000; 39(8):857-864.
43
- 44 (37) Kumar K, Daley E, Khattak F, Buckley CD, Raza K. The influence of ethnicity on the extent of,
45 and reasons underlying, delay in general practitioner consultation in patients with RA.
46 *Rheumatology (Oxford)* 2010; 49(5):1005-1012
47
48
- 49 (38) Tiwana R, Rowland J, Fincher M, Raza K, Stack RJ. Social interactions at the onset of
50 rheumatoid arthritis and their influence on help-seeking behaviour: A qualitative
51 exploration. *British journal of health psychology*. 2015 Sep;20(3):648-61.
52
- 53 (39) Mølbæk K, Hørslev-Petersen K, Primdahl J. Diagnostic delay in rheumatoid arthritis: a
54 qualitative study of symptom interpretation before the first visit to the doctor.
55 *Musculoskeletal care*. 2016 Mar;14(1):26-36.
56
57
58
59

- 1
2
3 (40) Simons G, Mallen CD, Kumar K, Stack RJ, Raza K. A Qualitative Investigation of the Barriers to
4 Help-seeking Among Members of the Public Presented with Symptoms of New-onset
5 Rheumatoid Arthritis. *J Rheumatol* 2015; 42(4):585-592.
6
7 (41) Sheppard J, Kumar K, Buckley CD, Shaw KL, Raza K. 'I just thought it was normal aches and
8 pains': a qualitative study of decision-making processes in patients with early rheumatoid
9 arthritis. *Rheumatology (Oxford)* 2008; 47(10):1577-1582.
10
11 (42) Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the
12 onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative
13 literature. *Ann Rheum Dis* 2012; 71(4):493-497.
14
15 (43) Townsend A, Wyke S, Hunt K. Self-managing and managing self: practical and moral
16 dilemmas in accounts of living with chronic illness. *Chronic Illn* 2006; 2(3):185-194.
17
18 (44) Scott IC, Mangat N, MacGregor A, Raza K, Mallen CD, Hider SL. Primary care challenges in
19 diagnosing and referring patients with suspected rheumatoid arthritis: a national cross-
20 sectional GP survey. *Rheumatology Advances in Practice*. 2018 Apr 6;2(1):rky012.
21
22 (45) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed
23 analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis
24 patients. *Scand J Rheumatol* 2014; 43(1):1-8.
25
26 (46) Simons G, Belcher J, Morton C, Kumar K, Falahee M, Mallen CD, Stack RJ, Raza K. Symptom
27 Recognition and Perceived Urgency of Help-Seeking for Rheumatoid Arthritis and Other
28 Diseases in the General Public: A Mixed Method Approach. *Arthritis care & research*. 2017
29 May;69(5):633-41.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes (Page 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes (page 4)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes (pages 5-7)
Objectives	3	State specific objectives, including any prespecified hypotheses	Yes (pages 6-7)
Methods			
Study design	4	Present key elements of study design early in the paper	Yes (page 1, and page 7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes (page 7- 9)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Cross-sectional study – Yes (Page 7)
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
Variables	7	<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Yes (page 7-8)
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes (page 7-8, also see table 1)
Bias	9	Describe any efforts to address potential sources of bias	Yes (Pages 17-22)
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes (page 10)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes (page 10)

1		
2	(b) Describe any methods used to examine subgroups and	Yes
3	interactions	
4	(c) Explain how missing data were addressed	
5	(d) Cohort study—If applicable, explain how loss to follow-	N/A
6	up was addressed	
7	Case-control study—If applicable, explain how matching of	
8	cases and controls was addressed	
9	Cross-sectional study—If applicable, describe analytical	
10	methods taking account of sampling strategy	
11		
12	€ Describe any sensitivity analyses	
13		

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Yes (pages 17-18)
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Yes (pages 17-18)
		(b) Indicate number of participants with missing data for each variable of interest	Yes (table 1)
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	N/A
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	Yes (pages 17-18)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A

Discussion

Key results	18	Summarise key results with reference to study objectives	Yes (Page 22)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes (page 20)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes (page 20-22)
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes (page 22)

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes (page 25)
---------	----	---	---------------

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
4 available at www.strobe-statement.org.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024361.R2
Article Type:	Research
Date Submitted by the Author:	29-Nov-2018
Complete List of Authors:	Stack, Rebecca; Nottingham Trent University , Division of Psychology Nightingale, Peter; Queen Elizabeth Hospital Birmingham, Wellcome Trust Clinical Research Facility Jinks, Clare; Keele University, Arthritis Research UK Primary Care Centre Study Syndicate, DELAY Shaw, Karen; University of Birmingham, Institute of Applied Health Research Herron-Marx, Sandy; Independent Research Consultant Horne, Rob; UCL, UCL School of Pharmacy Deighton, Chris; Derby Teaching Hospitals NHS Foundation Trust Kiely, Patrick ; St George's University Hospitals NHS Foundation Trust Mallen, Christian; Keele University, Arthritis Research UK Primary Care Centre Raza, Karim; University of Birmingham, Institute of Inflammation and Ageing
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Health services research, Rheumatology
Keywords:	RHEUMATOLOGY, access to care, help seeking, health service research, rheumatoid arthritis

SCHOLARONE™
Manuscripts

1
2
3 **Title: Delays between the onset of symptoms and first rheumatology consultation in**
4
5 **patients with rheumatoid arthritis in the UK: an observational study**
6
7
8
9

10 **Authors**

11
12 Rebecca J Stack^{1,2}, Peter Nightingale³, Clare Jinks⁴, (DELAY study syndicate), Karen Shaw⁵,
13
14 Sandy Herron-Marx⁶, Rob Horne⁷, Chris Deighton⁸, Patrick Kiely⁹, Christian D Mallen⁴ and
15
16 Karim Raza^{1,10}
17
18
19
20
21
22

23 **Department and Institutions**

- 24
25 1. Institute of Inflammation and Ageing, University of Birmingham, UK.
26
27 2. Division of Psychology, Nottingham Trent University, Nottingham, UK
28
29 3. Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation
30
31 Trust, Birmingham, UK.
32
33 4. Research Institute for Primary Care and Health Sciences, Keele University, UK.
34
35 5. Institute of Applied Health Research, University of Birmingham, UK
36
37 6. Independent Research Consultant, Brussels, Belgium.
38
39 7. School of Pharmacy, University of London, UK.
40
41 8. Department of Rheumatology, Derby Hospitals NHS Foundation Trust, Derby, UK.
42
43 9. Department of Rheumatology, St Georges University Hospital NHS Foundation Trust,
44
45 London, UK.
46
47 10. Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust,
48
49 Birmingham, UK.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Corresponding author**
4
5

6 Professor Karim Raza
7

8 Rheumatology Research Group
9

10 Institute of Inflammation and Ageing (IIA)
11
12

13 University of Birmingham
14

15 Queen Elizabeth Hospital, Birmingham, B15 2WB
16

17 E mail : k.raza@bham.ac.uk
18
19
20
21
22

23 **Word Count** (excluding title page, abstract, references and tables): 2499
24
25
26
27
28
29

30 **Keywords**
31

32 Rheumatoid arthritis; patient delay; Primary care delay; help-seeking; access to care;
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Strengths and limitations of this study.**
4

5
6 A key strength of this study is that it surveyed a large sample of patients with new onset
7
8 rheumatoid arthritis in the UK to identified delays in access to care.
9

10
11 Limitations include the fact that data were collected at the point of diagnosis and
12
13 information regarding key dates (in particular the onset of symptoms and presentation to
14
15 primary care) were reliant on patient recall.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: To investigate delays from symptom onset to rheumatology assessment for patients with a new onset of rheumatoid arthritis (RA) or unclassified arthritis.

Methods: Newly presenting adults with either RA or unclassified arthritis were recruited from rheumatology clinics. Data on the length of time between symptom onset and first seeing a GP (patient delay), between first seeing a GP and being referred to a rheumatologist (general practitioner delay) and being seen by a rheumatologist following referral (hospital delay) were captured.

Results: 822 patients participated (563 female, mean age 55 years). The median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4–26.3 weeks). Patients who purchased over the counter medications or used ice/heat packs took longer to seek help than those who did not. In addition, those with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset. The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks). Patients made a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Conclusion: This study identified delays at all levels in the pathway towards assessment by a Rheumatologist. However, delays in primary care were particularly long. Patient delay was driven by the nature of symptom onset. Complex multi-faceted interventions to promote rapid help seeking and to facilitate prompt onward referral from primary care should be developed.

Introduction:

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately 1% of the population.^{1,2} Rheumatoid arthritis is associated with significant morbidity in large part as a consequence of extra-articular co-morbidities associated with systemic inflammation. In the UK it has been estimated that RA costs the NHS around £560 million per year and that additional costs to the economy of sick leave and work-related disability total £1.8 billion per year.³ The first three months following the onset of RA symptoms represents an important therapeutic window.⁴ Treatment during this phase improves long-term clinical outcomes, increasing the proportion of patients whose disease enters remission, reducing RA related joint damage and reducing the eventual need for joint replacement surgery.⁵⁻¹⁰ Therefore, it is vital that patients are seen by Rheumatologists rapidly following the onset of RA symptoms to allow the rapid introduction of disease modifying anti-rheumatic drug treatment. However, despite increased recognition of the benefits of early treatment there remains considerable delay between symptom onset and the initiation of therapy.¹¹⁻¹³ Indeed a report by the UK's National Audit Office (NAO) in 2009 estimated that only 10% of patients with RA were treated within three months of symptom onset. The NAO's modelling suggested significant financial benefits for the broader economy and quality of life benefits for the individual if the proportion of patients treated earlier was increased.³

The patient's pathway to care can be delayed for a number of reasons, including delays on the part of the patient in recognising the significance of the early symptoms of RA.¹⁴⁻¹⁶ Recent

1
2
3 research has linked patients' perceptions of RA and coping styles to the length of time taken
4 to seek help.¹⁷ Before seeking medical help from a physician, patients may seek help from a
5 range of services including complementary therapists, pharmacists and telephone and on-line
6 services. However, the use of these services at the onset of inflammatory arthritis has not
7 been fully explored. Primary healthcare professionals often find the early symptoms of RA
8 difficult to distinguish from those of other rheumatic diseases, making timely and appropriate
9 referrals to rheumatologists challenging.^{18;19} There may thus be delays in healthcare
10 professionals making a referral to a Rheumatologist and also in assessment at the secondary
11 care level, contributing further to the delay in making a diagnosis and commencing
12 appropriate therapy.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 Several studies conducted across a range of countries have shown long delays between the
31 onset of symptoms and a patient's first consultation with a rheumatologist.²⁰⁻²³ However,
32 data related to lengths of time between the onset of inflammatory musculoskeletal
33 symptoms and first seeing a GP, between first seeing a GP and being referred to a
34 rheumatologist and being seen by a rheumatologist following referral were not available
35 across multiple NHS Trusts in multiple regions of the UK at the time of this study.

36 37 38 39 40 41 42 43 44 45 46 47 **Aim**

48
49 The aim of this study was to investigate the extents of delay in assessment of patients with
50 RA and unclassified arthritis. Specifically the study assessed extents of delay at the level of
51 the patient in seeking help from the general practitioner, the general practitioner in
52 referring to a Rheumatologist and the Rheumatologist in assessing the patient following
53 referral. The relationships between extents of delay and clinical and demographic variables
54
55
56
57
58
59
60

1
2
3 were explored and data captured relating to sources of information, help and advice utilized
4
5 by patients prior to GP consultation.
6
7
8
9

10 **Methods**

11
12 A questionnaire based survey of consecutively presenting patients with a new onset of RA or
13
14 unclassified inflammatory arthritis was undertaken in England and Scotland. Networks such
15
16 as the Early Rheumatoid Arthritis Network²⁴ and the National Institute for Health Research
17
18 Clinical Research Network²⁵ were used identify Rheumatology centres to participate in this
19
20 study. RJS also promoted the study during abstract presentations at British Society for
21
22 Rheumatology meetings.
23
24
25
26
27
28
29

30 Data were collected from Rheumatology departments in 34 NHS Trusts. Rheumatology
31
32 departments were secondary care based, although one rheumatology department
33
34 (Sandwell and West Birmingham Hospitals) operated clinics in both hospital and community
35
36 settings. Eligible patients were recruited on their first or second visit to the rheumatology
37
38 department following a primary care referral (data were not collected on the numbers of
39
40 patients whose data were collected at their first visit or at their second visit). Rheumatologists
41
42 were asked to approach consecutively presenting patients who met the eligibility criteria.
43
44
45
46 Eligible patients were newly referred adults (aged ≥ 18 years) with clinically apparent
47
48 synovial swelling of one or more joints who had either a new onset of RA (according to 2010
49
50 ACR / EULAR criteria ²⁶) or unclassified arthritis (UA; defined as a failure to fulfil classification
51
52 criteria for another inflammatory rheumatic disease). Patients with UA were recruited, as in
53
54 many cases patients with UA at initial secondary care assessment progress to RA over
55
56
57
58
59 time.²⁷
60

1
2
3
4
5
6 Data were collected using two questionnaires (available from the corresponding author on
7
8 request). First, following consent, the recruiting healthcare professional, with the patient
9
10 present, completed a questionnaire that captured data on extents of delays between [1]
11
12 symptom onset and seeing a healthcare professional (from herein referred to as 'patient
13
14 delay', these data was gathered from the patient's account by the recruiting healthcare
15
16 professional), [2] seeing a general practitioner and being referred to a rheumatologist (from
17
18 herein referred to as 'general practitioner e delay', these data was gathered from the
19
20 patient's account by the recruiting healthcare professional), and [3] being referred to a
21
22 rheumatologist and seeing a rheumatologist (from herein referred to as 'hospital delay',
23
24 these data were gathered from referral letters and hospital notes). Data were also gathered
25
26 on [1] demographic variables including the patient's age, gender, education, employment
27
28 status and postcode; deprivation ranks were calculated from postcode data using
29
30 Geoconvert 2010 which produced an Index of Multiple Deprivation (IMD) score,²⁸ [2] clinical
31
32 variables including the mode of symptom onset (palindromic (defined as intermittent
33
34 symptoms) vs. non-palindromic (defined as persistent symptoms)), rapidity of symptom
35
36 onset (acute vs. insidious; an acute onset was typically viewed as an onset of symptoms
37
38 which came on rapidly over 24-48 hours), duration of morning stiffness, swollen and tender
39
40 joint counts, Disease Activity Score 28 (DAS28) and fulfilment of 2010 ACR/EULAR criteria for
41
42 classification of RA²⁶.

43
44
45
46
47
48
49
50
51
52
53
54 In addition, via a separate questionnaire that patients completed by themselves, patients
55
56 provided data on actions taken in relation to their symptoms prior to seeking help from
57
58 primary care . The variables captured were informed by previous qualitative research,
59
60

1
2
3 including patient interviews and interviews with healthcare professionals. In addition, we
4
5 had input from Patient Research Partners and the questions asked were validated and
6
7 assessed for reliability²⁹.
8
9

10 11 12 13 **Patient and Public Involvement**

14
15 Patient and public involvement was an important element of this study. Patient
16
17 representatives from Sandwell and West Birmingham Hospitals NHS Trust were involved in
18
19 the study design, advised on the content of patient facing materials including participant
20
21 information sheets and consent forms and the content of questionnaires including
22
23 questions related to actions taken by patients prior to consulting their GPs. Patients were
24
25 members of the Project Management Group reviewing study recruitment and supporting
26
27 the Group in developing approaches to ensure that recruitment proceeded to time and
28
29 target
30
31
32
33
34
35
36
37

38 **Analysis**

39
40
41 To ensure that the data met parametric assumptions, the distribution and levels of
42
43 multicollinearity between variables were checked. Data on patient delays, general
44
45 practitioner delays and hospital delays were not normally distributed, therefore, log values
46
47 of these delay data were created to generate normally distributed variables.
48
49
50

51
52 For each of the outcomes patient delay, general practitioner delay and hospital delay a
53
54 general linear model was used with main effects and two-way interactions for the following
55
56 explanatory variables: gender, ethnicity, IMD score, age, education, employment status,
57
58 mode of onset, rapidity of onset, patient reported family history of RA and RA vs. UA. For
59
60

each outcome any two-way interactions which were not significant were removed in a backwards stepwise fashion, with the pairings with the highest p values being removed first. All main effects were retained, so that the final model for each outcome included all ten explanatory variables and any significant two-way interactions ($p < 0.01$). All significant main effects and interactions are reported in the Results section.

Results

1. Participant characteristics

Data were collected from 856 patients between 2011 and 2014. Patients were withdrawn from the study due to incomplete data (21 cases) and ineligibility (13 cases in whom there was no clinical synovitis reported at recruitment). Data were thus analysed from 822 patients of whom 68.5% were female with a mean age of 55 years. Characteristics of patients are presented in table 1.

Table 1: Demographic and disease related characteristics of patients. Data are presented as either percentage (number) or median (IQR) as appropriate. Tender joint count is out of 42 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 hip, 2 knee, 2 ankle, 10 MTP). Swollen joint count is out of 40 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 knee, 2 ankle, 10 MTP).

Female	68.5% (563)
Age, years	57 (45-67)
Diagnosis of RA	73% (603)
Ethnicity: Black British	6.0% (49)

South Asian	7.7% (63)
White British	84.9% (698)
Other	1.5% (12)
Self-reported family history of RA	34.9% (287)
Palindromic onset	42.8% (352)
Acute onset	35.9% (295)
Duration of morning stiffness, minutes	60 (10-120)
DAS28	4.88 (3.98 -5.80)
HAQ	1.13 (0.50-1.73)
Tender joint count	9 (4-18)
Swollen joint count	5 (2-10)

2. Intervals between symptom onset and first rheumatology consultation

Overall the median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1 – 66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks). The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks) with patients making a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

1
2
3 *Palindromic onset is defined as intermittent symptoms, while non-palindromic is defined as persistent*
4 *symptoms. Acute onset defined as symptoms which came on rapidly over 24-48 hours, while insidious*
5 *onset is defined as symptoms which developed slowly over an extended period of time. Patients*
6
7
8
9
10 with a palindromic symptom onset had a significantly longer patient delay than those with a
11
12 non-palindromic onset (9.3 weeks (IQR 2-43 weeks) vs 4.3 weeks (IQR 1-17 weeks); $p < 0.001$,
13
14 t-test). Furthermore, those with an acute symptom onset had significantly shorter patient
15
16 delays than those with an insidious symptoms onset (2.4 weeks (IQR 1 - 6.6 weeks) vs 11.1
17
18 weeks (IQR 4-44 weeks; $p < 0.001$, t-test).
19
20
21
22
23
24
25

26 *Resources used before seeking help from primary care*

27
28
29 Patients reported taking a range of actions in relation to their symptoms before seeking help
30
31 from their GP and in some cases these actions were associated with longer delays in GP
32
33 consultation (see table 2). Most often patients reported purchasing tablets from 'the
34
35 chemist', although only a small proportion actually reported speaking to a pharmacist.
36
37
38 Other actions reported by patients included applying heat or cold packs to joints or buying
39
40 joint supports.
41
42
43
44
45
46
47

48 **Table 2.** *Actions taken by patients with inflammatory arthritis before seeking help from their*
49 *GP with comparison made for patient delay between those who did and did not undertake*
50 *this action using independent t-tests; * P value for comparison of those who did and did not*
51 *undertake this action.*
52
53
54
55
56
57
58
59
60

Actions taken before seeking help from GP	% (number) of participants undertaking this action	Median (IQR) patient delay in weeks for those undertaking this action	Median (IQR) patient delay in weeks for those not undertaking this action	P value
Bought tablets from the chemist	51.1% (273 out of 534)	6.9 (2-30.7)	4.7 (1.4-23)	p=0.036
Used an ice or heat pack on joint	47.8% (254 out of 531)	7.6 (2-30.3)	4.9 (2-26.1)	p=0.045
Took baths	47.4% (251 out of 529)	6.3 (2-30.4)	5.6 (2-26.1)	p=0.473
Bought joint supports (splints, tubi-grips etc)	37.4% (198 out of 529)	4.4 (2.1-18.6)	5.1 (2-26.9)	p=0.362
Used alternative therapies	25.2% (134 out of 531)	8.3 (2-42.1)	5.3 (2-26.3)	p=0.020
Bought products from a health shop	19.0% (101 out of 532)	5.9 (2-36.3)	5.9 (2-26)	p=0.182
Modified diet	14.4% (76 out of 529)	6 (2.1-35.3)	6.1(2-26.3)	p= 0.183

Used prayer or sought spiritual guidance	8.4% (45 out of 534)	4.4 (2.1-18.6)	6.3 (2-26.9)	p=0.941
Spoke to a pharmacist	7.9% (41 out of 521)	5.9 (2-38.1)	5.9 (2-26.3)	p=0.544

Thirty-seven percent of patients reported looking on the internet (for example visiting the NHS direct website, BUPA website, Arthritis Research UK website and searching for information using search engines such as Google). Patients also reported seeking support via a telephone helpline; 5.7% described calling the NHS direct helpline or another telephone health advice service. 3.7% sought help in the workplace (e.g. from an occupational nurse), 2% of patients went directly to the Accident and Emergency Department and 1% attended an NHS walk-in centre.

Multivariate analysis: Patient delay

The interaction model showed main effects for mode of onset (palindromic vs. non-palindromic; $F=26.65$, $P<0.01$) and rapidity of onset (acute vs. insidious; $F=65.36$, $P<0.01$). An interaction was found between palindromic onset and gender ($F=45.658$, $P<0.01$); men with a palindromic onset waited significantly longer before seeking help.

Multivariate analysis: General practitioner delay

A main effect was found for ethnicity ($F=6.26$, $P<0.01$). Significant differences in general practitioner delay were found between White British and South Asian patients (6.2 weeks (IQR 2-18.6) vs 22 weeks (IQR 6.5-39.8); $P<0.001$) and between White British and Black British patients (6.2 weeks (IQR 2-18.6) vs 11.1 weeks (IQR 4.3-21.7); $P<0.001$). No significant difference was found between South Asian and Black British patients ($P=1.000$).

A main effect was also found for family history ($F=5.89$, $P<0.01$); the median general practitioner delay for those with a self-reported family history of RA was 9 weeks (IQR 2.4-25.7), while general practitioner delay for those with no family history was 6.3 weeks (IQR 2.3-19). Interactions at a statistically significant level (<0.01) were not found.

Multivariate analysis: Hospital delay

The original model included main effects and two-way interactions for the following explanatory variables: gender, ethnicity, IMD score, age, education, employment status, mode of onset, rapidity of onset, family onset and RA vs. UA. None of the main effects or interactions (when removed backwards) were significant in predicting the delay between referral and being seen in secondary care.

Discussion

International guidelines recommend that the treatment of RA should begin as soon as possible after the onset of symptoms, ideally aiming to capture patients within the first 3 months following symptom onset. However, this large UK study of delays in access to care for RA patients found that the median patient delay in seeking help at the onset of symptoms was 5.4 weeks, while the median delay between seeing a healthcare professional and being referred was 6.9 weeks. Our study highlights that only 20% of patients were seen within the first 3 months of symptom onset. This appears to be lower than the rate reported in other European countries for example a recent study in Austria reported that 38% of patients were seen within the first 3 months³⁰. The present study also found an average delay of 4.7 weeks from referral until the patient was seen by a rheumatologist, similar to figures reported in the NAO report³. Unlike our previous study conducted at a single centre in the UK where patient delay accounted for the largest element of delay,¹³ we found that GP delay was the largest contributor to overall delay; patient delay was less than we had previously reported in our single centre study.

This research highlights that delays in primary care are long, and a major contributor to overall delays between symptom onset and the first rheumatology visit. General practitioners are faced with a number of barriers to identifying patients with newly presenting RA including the often non-specific nature of symptoms at the earliest stages of RA.¹⁸ Research is underway to define symptom complexes most predictive of RA development in patients with newly presenting musculoskeletal symptoms. For example, a questionnaire has been developed and validated to capture such symptoms in patients

1
2
3 presenting with joint symptoms which by history are suggestive of an underlying
4
5 inflammatory cause³¹ and data are currently being collected from such patients in secondary
6
7 care based longitudinal observational cohort studies to identify symptoms that may predict
8
9 RA development. Furthermore an assessment of primary care databases has identified a
10
11 range of symptoms including hand related joint symptoms, morning stiffness and carpal
12
13 tunnel syndrome type symptoms as being ones with which patients frequently present to
14
15 the GP prior to the point at which the GP refers the patient to a Rheumatologist or records a
16
17 diagnosis of RA ³² It is likely that a combination of education, and evidence based referral
18
19 algorithms, will be needed to ensure that suspected cases are referred early. For example,
20
21 in Fife, Scotland GPs did not have access to rheumatoid factor testing during the course of
22
23 our study, and used guidelines with pictorial representations to help identify early synovitis
24
25 (personal communication Dr Helen Harris). Fife was a participating centre in this study, and
26
27 was found to have the lowest GP referral time of all centres surveyed. Furthermore,
28
29 facilitating access to secondary care, for example through the establishment of rapid
30
31 assessment clinics whose main aim is to identify whether the patient does or does not have
32
33 synovitis have been shown to significantly reduce delays in the assessment of patients.³³ A
34
35 limitation of our research is that the study was not able to assess regional differences across
36
37 NHS Trusts. A study comparing delays and referral patterns between hospitals with local
38
39 policies and practices which may influence the time between onset and first consultation
40
41 would be useful and an international study would be particularly helpful. In addition, this
42
43 study did not examine the distances between patients' homes and their local GP surgeries,
44
45 and hospital and so we were unable to assess whether physical distance between the
46
47 patient's home and the GP surgery or hospital influenced delay.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A number of factors were found to influence GP delay including ethnicity. Studies in the field
4
5 of oncology have also found that people from ethnic minority backgrounds face longer GP
6
7 delays.^{34;35} In the context of RA it is possible that the early symptomatology of patients from
8
9 ethnic minority backgrounds is different from, and less typical of RA than that of, patients of
10
11 white British background, thus making recognition more challenging for GPs. Data certainly
12
13 exist that the clinical phenotype of established RA differs in patients of South Asian origin
14
15 compared with patients of White British origin,³⁶ though data relating the clinical
16
17 presentations of RA in these groups are lacking. Furthermore, it is unclear why a self-
18
19 reported family history of RA would be associated with longer delays although it is
20
21 important to recognise that GPs may not have elicited this information from the patient.³⁷
22
23 Qualitative approaches may be helpful to address some of these issues in the future.
24
25
26
27
28
29
30
31

32
33 Previous qualitative studies and a meta-synthesis have identified barriers to help seeking at
34
35 the onset of RA.³⁷⁻⁴³ The present study identifies that before seeking formal medical
36
37 attention, people experiencing the early symptoms of RA seek information and help from a
38
39 number of alternative sources and often self-medicate. We identified that buying tablets
40
41 from a pharmacy, and using heat or ice on joints was significantly associated with longer
42
43 patient delays. This finding highlights that some self-management behaviours, particularly
44
45 those linked to accessing pharmacy services can negatively impact on the time it takes to
46
47 seek help; this needs further exploration. Factors previously suggested to be associated
48
49 with delays in GP consultation included an insidious onset of mild symptoms and a lack of
50
51 knowledge about RA, personal susceptibility to RA and the availability of treatments to slow
52
53 disease progression. In our national sample 64.1% of people describe an insidious onset of
54
55 RA, and 42.8% describe a palindromic onset of RA. Therefore, majority large proportion of
56
57
58
59
60

1
2
3 patients surveyed experienced a slow and / or intermittent onset of their inflammatory joint
4
5 symptoms. Our quantitative data are thus consistent with results from qualitative studies,
6
7 demonstrating that the mode and rapidity of onset of symptoms is significantly associated
8
9 with patient delays.
10
11

12
13 This study has a number of limitations. Firstly, the interval between first consultation with a
14
15 Rheumatologist and initiation of disease modifying anti-rheumatic drug (DMARD) treatment
16
17 was not measured. Any additional delay in commencing DMARD treatment will negatively
18
19 impact the patient and variables associated with delays at this level should be assessed in
20
21 future studies. Secondly, during the course of this study a number of guidelines related to
22
23 RA management were published which may have influenced practice, and patterns of
24
25 referral. We were not able to explore the relationships between the availability / local
26
27 adoption of guidelines and delays in the assessment of patients. Future investigation should
28
29 assess the impact of policy changes on patterns of help-seeking, referral and assessment.
30
31
32 Thirdly, the rheumatology centres participating in this study were self-selecting, therefore,
33
34 there may be biases in the characteristics of the rheumatology centres which participated in
35
36 this study. For example, the participating rheumatology units may have had a particular
37
38 interest in early arthritis. Only a study which recruited consecutive patients from all
39
40 rheumatology units across the UK would be able to provide a truly national picture.
41
42
43 Fourthly, whilst we were able to document the length of delay at a primary care level there
44
45 were important variables which may have influenced this delay which we did not record and
46
47 so were unable to explore. For example it would have been helpful have access to results
48
49 tests performed in primary care to assess whether levels of inflammatory markers or RA
50
51 related autoantibodies measured in primary care influenced the rapidity of referral from
52
53 primary care. Indeed a recent quantitative survey of GPs' anticipated actions in primary care
54
55
56
57
58
59
60

1
2
3 when dealing with patients with suspected RA suggest that results of these tests may
4 influence GP behaviours⁴⁴. Future research should address this. Similarly, a number of
5 secondary care related variables may have influenced the extent of secondary care delay
6 including the number of rheumatologists at each Trust, whether a dedicated early arthritis
7 clinic was in place and approaches taken to the triage of referrals. Data relating to these
8 variables were not collected though future work addressing issues of delay should address
9 these important issues. Fifthly, data relating to the dates of onset of symptoms and initial
10 GP consultation were gathered from patients' histories, and therefore relied on patient
11 recollection with a possible associated error. However, a previous study addressing delays in
12 the assessment of patients with RA, compared patient accounts of their journeys to first
13 rheumatology consultation against medical records and highlighted the accuracy of patient
14 recollection in relation to dates found to be documented in primary care records⁴⁵. This, to
15 some extent, validates our approach of using patient memory to define the dates of
16 symptom onset and initial GP presentation. An alternative approach would be a
17 longitudinal observational study in the general population to track the development of
18 symptoms and the relationship between that and GP consultation, GP referral and
19 secondary care assessment. A challenge with this approach is the low incidence of RA and
20 thus the requirement for a very large sample size. One could potentially enrich the
21 population for RA risk by, for example, following individuals who are at increased risk of RA
22 (e.g. the first degree relatives of patients with RA). However, one of the challenges with this
23 strategy is that simply being involved in such a study may influence subsequent patient and
24 GP behaviour.

1
2
3 Whilst delays in primary care are the largest contributor to overall delay, patient delay and
4 hospital delay represent important components. This study found that the nature of
5 symptoms onset influenced how quickly patients with RA sought help, suggesting that those
6 with an acute onset of persistent symptoms seek help faster than those with insidious and
7 palindromic onsets. Interventions to encourage rapid help seeking should consider
8 highlighting the frequently insidious onset of RA to members of the public stressing that
9 help should be sought even when symptoms are mild. However, even those with a rapid
10 onset of persistent symptoms often delayed for prolonged periods before seeking help. We
11 have previously shown that members of the public view musculoskeletal symptoms, even
12 those with clear inflammatory features, as less worrisome and less requiring rapid
13 assessment as compared with symptoms of other common diseases such as ischaemic type
14 chest pain or bowel disturbance with associated rectal blood loss⁴⁶. Enhanced public
15 education to highlight the significance of inflammatory type musculoskeletal symptoms is
16 thus likely to be needed. Interventions at multiple levels, including at the levels of the
17 public, the services which members of the public consult after the onset of symptoms (e.g.
18 pharmacies), primary care and secondary care will be needed to reduce overall delays in
19 access to appropriate specialists.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Competing interests

No competing Interest:

Contributorship

RJS, CJ, SHM, CDM, KS, RH, CD, PK and KR made substantial contributions to the conception or design of the work. The acquisition of data was undertaken by RJS, KR, PK and CD. RJS, CJ and SHM facilitated patient and public involvement in the design, delivery and interpretation of this study. The analysis and interpretation of data were undertaken by RJS, PN and KR. RJS, PN, CJ, SHM, CDM, KS, RH, CD, PK and KR were involved in drafting the work and revising it critically for important intellectual content. RJS, CJ, SHM, CDM, KS, RH, CD, PK and KR gave final approval of the version published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgements

We would like to thank the staff at the rheumatology departments who collected data for this study. We would also like to thank patient research partners at Sandwell and West Birmingham Hospitals NHS Trust for their help and support with this study.

Funding information

This article presents independent research funded in part by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (funder's reference PB-PG-1208-18114). CDM is funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research and a NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). CJ is part-funded by the NIHR Collaborations for Leadership in Applied Health Research and Care West Midlands. RH is part-funded by North Thames CLAHRC and his contribution was also supported by an NIHR Senior Investigator Award. KS is funded by the NIHR CLAHRC West Midlands initiative. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Ethical approval information Ethical approval was obtained from South Birmingham Research Ethics Committee (reference no. 10/H1207/98) and all participants gave written

1
2
3 informed consent. Data was stored in a secure location and protected by multiple security
4 systems.
5
6
7

8 **Data sharing statement**

9
10 Data are available upon request from the corresponding author.
11
12

13 **Exclusive Licence**

14
15 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
16 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
17 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
18 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
19 Federal Government officers or employees acting as part of their official duties; on a
20 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its
21 licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the
22 Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all
23 rights, as set out in our [licence](#).
24
25
26
27
28
29
30
31
32
33

34 The Submitting Author accepts and understands that any supply made under these terms is
35 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of
36 your employer or a postgraduate student of an affiliated institution which is paying any
37 applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting
38 Author wishes to make the Work available on an Open Access basis (and intends to pay the
39 relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
40 Commons licence – details of these licences and which [Creative Commons](#) licence will apply
41 to this Work are set out in our licence referred to above.
42
43
44
45
46
47
48
49
50

51 **Non-author contributors - Delay study syndicate**

52
53
54 Sandwell and West Birmingham Hospitals NHS Trust: Biruk Asfaw, Sabrina Kapoor, Kanta
55 Kumar, Adam Slater & Christopher Buckley
56
57

58 Derby Teaching Hospitals NHS Foundation Trust: Chris Deighton & Alison Booth
59
60

1
2
3 Nottingham University Hospitals NHS Trust: Marie-Josophe Pradere, Ira Pande & Ian
4
5 Gaywood
6
7 St George's University Hospitals NHS Trust: Francesca Leone & Patrick Keily
8
9 Lancaster Teaching Hospitals NHS Foundation Trust: Bronwen Evans & Marwan Bukhari
10
11 Poole Hospitals NHS Foundation Trust: Julia Taylor, Helena Knowles, & Sarah Westlake
12
13 University Hospitals Coventry and Warwickshire NHS Trust: Tanya Potter
14
15 Sherwood Forest Hospitals NHS Foundation Trust: Debbie Wilson, Jayne Smith & David
16
17 Walsh
18
19 King's College Hospitals NHS Foundation Trust: Nyarko Ahwireng, Audu Aderonke & David
20
21 Scott
22
23 Guy's and St Thomas NHS Foundation Trust: Louise Nel, Naomi Hare & Andrew Cope
24
25 North Bristol NHS Trust: Julie Taylor, Wendy Wilmott & Paul Creamer
26
27 West Hertfordshire Hospitals NHS Trust: Lynn Currie, Adam Young & Karen Markwell
28
29 Lewisham and Greenwich NHS Trust: Louise Pollard & Debbie Johnson
30
31 Royal Surrey Country NHS Foundation Trust: Stephanie Allen & Raad Makadsi
32
33 Hampshire Hospitals NHS Foundations Trust: Peter Prouse & Janet Cushnaghan
34
35 University Hospitals of Leicester NHS Trust: Jessy Sabu & Moorthy Arumugam
36
37 County Durham and Darlington NHS Foundation Trust: Matt Bridges & Pam Race
38
39 Weston Area Health NHS Trust: Dawn Symonds & Matt Bridges
40
41 University Hospitals Birmingham NHS Foundation Trust: Jackie Cobb, Andrew Filer, Simon
42
43 Bowman & Paresh Jobanputra
44
45 Royal Wolverhampton Hospital NHS Trust (at the time of recruitment the hospital from
46
47 which patients were recruited was within the Mid Staffordshire NHS Foundation Trust) :
48
49 Julie Edwards & Tom Sheeran
50
51 East Kent Hospitals University NHS Foundation Trust: Caroline Crowley & Imad Jassim
52
53 University Hospitals of the North Midlands NHS Trust: Julie Gray & Jon Packham
54
55 NHS Fife: Paul Allcoat & Helen Harris
56
57 Yeovil District Hospital NHS Foundation Trust: Rebecca Rowland & Sally Knights
58
59 Northumbria Healthcare NHS Foundation Trust AND The Newcastle Upon Tyne Hospitals
60
NHS Foundation Trust: Peta Heslop, Sandra Robinson, David Walker, Heather Russell &
Sheryl Mitchell
Chesterfield Royal Hospital NHS Foundation Trust: Heather Cripps & Kevin Fairburn

1
2
3 Lancashire Teaching Hospitals NHS Foundation Trust AND East Lancashire Hospital NHS

4
5 Trust: Sue Cotterell, Gillian Welch, Ayesha Madan & Lee Suan Teh

6
7 Cambridge University Hospitals NHS Foundation Trust: Lucy Winstanley & Shweta Bhagat

8
9 The Dudley Group NHS Foundation Trust: Lucy Kadiki, Chitra Ramful & Ravinder Sandhu

10
11 Royal Cornwall Hospitals NHS Trust: Amanda Datson,& Anthony Woolf

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference List

- (1) Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2012; 72(8):1315-1320.
- (2) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002; 41(7):793-800.
- (3) National Audit Office. Services for people with rheumatoid arthritis. National Audit Office . 2009. London, The Stationery Office. 24-1-2013.
- (4) van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. *Ann Rheum Dis* 2015; 74(5):806-812.
- (5) Feldman DE, Bernatsky S, Houde M, Beauchamp ME, Abrahamowicz M. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? *Rheumatology (Oxford)* 2013; 52(3):452-459.
- (6) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906-914.
- (7) Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2006; 20(5):849-863.
- (8) Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? *Ann Rheum Dis* 2015; 74(5):793-794.
- (9) Scott DL, Hunter J, Deighton C, Scott DG, Isenberg D. Treatment of rheumatoid arthritis is good medicine. *BMJ* 2011; 343:d6962.
- (10) van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum* 2010; 62(12):3537-3546.
- (11) Feldman DE, Bernatsky S, Haggerty J, Leffondre K, Tousignant P, Roy Y et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2007; 57(8):1419-1425.
- (12) Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009; 48(1):57-60.
- (13) Kumar K, Daley E, Carruthers DM, Situnayake D, Gordon C, Grindulis K et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. *Rheumatology (Oxford)* 2007; 46(9):1438-1440.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (14) Stack RJ, Simons G, Kumar K, Mallen CD, Raza K. Patient delays in seeking help at the onset of rheumatoid arthritis: the problem, its causes and potential solutions. *Aging Health* 2013; 9(4):425-435.
 - (15) Oliver S, Bosworth A, Airoldi M, Bunyan H, Callum A, Dixon J et al. Exploring the healthcare journey of patients with rheumatoid arthritis: a mapping project - implications for practice. *Musculoskeletal Care* 2008; 6(4):247-266.
 - (16) Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, Hazes JM et al. A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. *Ann Rheum Dis* 2012; 27(1):13-22.
 - (17) Van der Elst K, De CD, Vecoven E, Arat S, Meyfroidt S, Joly J et al. Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. *Scand J Rheumatol* 2015;1-8.
 - (18) Stack RJ, Llewellyn Z, Deighton C, Kiely P, Mallen CD, Raza K. General practitioners' perspectives on campaigns to promote rapid help-seeking behaviour at the onset of rheumatoid arthritis. *Scand J Prim Health Care* 2014; 32(1):37-43.
 - (19) Stack RJ, Shani M, Mallen CD, Raza K. Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013; 65(12):1916-1926.
 - (20) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. *Scand J Rheumatol* 2014; 43(1):1-8
 - (21) van Nies JA, Brouwer E, de Rooy DP, van Gaalen FA, Huizinga TW, Posthumus MD et al. Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. *Ann Rheum Dis* 2013; 72(8):1302-1307.
 - (22) Zafar S, Badsha H, Mofti A, Delosantos A, Altares J, Matudio G et al. Efforts to increase public awareness may result in more timely diagnosis of rheumatoid arthritis. *J Clin Rheumatol* 2012; 18(6):279-282.
 - (23) Nanji JA, Choi M, Ferrari R, Lyddell C, Russell AS. Time to consultation and disease-modifying antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta perspective. *J Rheumatol* 2012; 39(4):707-711.
 - (24) Garwood W. The Early Rheumatoid Arthritis Network (ERAN). *Musculoskeletal care*. 2004 Nov;2(4):240-4.
 - (25) The National Institute for Health Research Clinical Research Network. <https://www.nihr.ac.uk/about-us/how-we-are-managed/managing-centres/crn/> (accessed 16th August 2018)
 - (26) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010; 69(9):1580-1588.

- 1
2
3 (27) van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al.
4 Validation of a prediction rule for disease outcome in patients with recent-onset
5 undifferentiated arthritis: moving toward individualized treatment decision-making. *Arthritis*
6 *Rheum* 2008; 58(8):2241-2247.
7
8 (28) Midas. GeoConvert. <http://geoconvert.mimas.ac.uk>. 2010.
9
10
11 (29) Stack RJ, Mallen CD, Deighton C, Kiely P, Shaw KL, Booth A et al. The development and initial
12 validation of a questionnaire to measure help-seeking behaviour in patients with new onset
13 rheumatoid arthritis. *Health Expect* 2014; Jun(3):1-10.
14
15 (30) Puchner R, Janetschko R, Kaiser W, Linkesch M, Steininger M, Termetsberger R et al. Efficacy
16 and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort
17 Study. *Journal of Rheumatology* 2016; 43(6):1130-1135.
18
19 (31) van Beers-Tas MH, ter Wee MM, van Tuyl LH, Maat B, Hoogland W, Hensvold AH, Catrina AI,
20 Mosor E, Stamm TA, Finckh A, Courvoisier DS. Initial validation and results of the Symptoms
21 in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project. *RMD*
22 open. 2018 May 1;4(1):e000641.
23
24 (32) Muller S, Hider S, Machin A, Stack R, Hayward RA, Raza K, Mallen C. Searching for a
25 prodrome for rheumatoid arthritis in the primary care record: A case-control study in the
26 clinical practice research datalink. In Seminars in arthritis and rheumatism 2018 Jun 23. WB
27 Saunders.
28
29 (33) van Nies JA, Brouwer E, van Gaalen FA, Allaart CF, Huizinga TW, Posthumus MD et al.
30 Improved early identification of arthritis: evaluating the efficacy of Early Arthritis
31 Recognition Clinics. *Ann Rheum Dis* 2012; 72(8):1295-301.
32
33 (34) Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in
34 breast cancer diagnosis by race, socioeconomic status, age and year. *Br J Cancer* 1992;
35 65(6):922-926.
36
37 (35) Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast
38 cancer diagnosis in young women by race/ethnicity. *JAMA Surg* 2013; 148(6):516-523.
39
40 (36) Griffiths B, Situnayake RD, Clark B, Tennant A, Salmon M, Emery P. Racial origin and its effect
41 on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched
42 cross-sectional study. *Rheumatology (Oxford)* 2000; 39(8):857-864.
43
44 (37) Kumar K, Daley E, Khattak F, Buckley CD, Raza K. The influence of ethnicity on the extent of,
45 and reasons underlying, delay in general practitioner consultation in patients with RA.
46 *Rheumatology (Oxford)* 2010; 49(5):1005-1012
47
48 (38) Tiwana R, Rowland J, Fincher M, Raza K, Stack RJ. Social interactions at the onset of
49 rheumatoid arthritis and their influence on help-seeking behaviour: A qualitative
50 exploration. *British journal of health psychology*. 2015 Sep;20(3):648-61.
51
52 (39) Mølbæk K, Hørslev-Petersen K, Primdahl J. Diagnostic delay in rheumatoid arthritis: a
53 qualitative study of symptom interpretation before the first visit to the doctor.
54 *Musculoskeletal care*. 2016 Mar;14(1):26-36.
55
56
57
58
59
60

- 1
2
3 (40) Simons G, Mallen CD, Kumar K, Stack RJ, Raza K. A Qualitative Investigation of the Barriers to
4 Help-seeking Among Members of the Public Presented with Symptoms of New-onset
5 Rheumatoid Arthritis. *J Rheumatol* 2015; 42(4):585-592.
6
7 (41) Sheppard J, Kumar K, Buckley CD, Shaw KL, Raza K. 'I just thought it was normal aches and
8 pains': a qualitative study of decision-making processes in patients with early rheumatoid
9 arthritis. *Rheumatology (Oxford)* 2008; 47(10):1577-1582.
10
11 (42) Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the
12 onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative
13 literature. *Ann Rheum Dis* 2012; 71(4):493-497.
14
15 (43) Townsend A, Wyke S, Hunt K. Self-managing and managing self: practical and moral
16 dilemmas in accounts of living with chronic illness. *Chronic Illn* 2006; 2(3):185-194.
17
18 (44) Scott IC, Mangat N, MacGregor A, Raza K, Mallen CD, Hider SL. Primary care challenges in
19 diagnosing and referring patients with suspected rheumatoid arthritis: a national cross-
20 sectional GP survey. *Rheumatology Advances in Practice*. 2018 Apr 6;2(1):rky012.
21
22 (45) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed
23 analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis
24 patients. *Scand J Rheumatol* 2014; 43(1):1-8.
25
26 (46) Simons G, Belcher J, Morton C, Kumar K, Falahee M, Mallen CD, Stack RJ, Raza K. Symptom
27 Recognition and Perceived Urgency of Help-Seeking for Rheumatoid Arthritis and Other
28 Diseases in the General Public: A Mixed Method Approach. *Arthritis care & research*. 2017
29 May;69(5):633-41.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes (Page 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes (page 4)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes (pages 5-7)
Objectives	3	State specific objectives, including any prespecified hypotheses	Yes (pages 6-7)
Methods			
Study design	4	Present key elements of study design early in the paper	Yes (page 1, and page 7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes (page 7- 9)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Cross-sectional study – Yes (Page 7)
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes (page 7-8)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes (page 7-8, also see table 1)
Bias	9	Describe any efforts to address potential sources of bias	Yes (Pages 17-22)
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes (page 10)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes (page 10)

1
2 (b) Describe any methods used to examine subgroups and Yes
3 interactions

4 (c) Explain how missing data were addressed

5 (d) *Cohort study*—If applicable, explain how loss to follow- N/A
6 up was addressed

7
8 *Case-control study*—If applicable, explain how matching of
9 cases and controls was addressed

10 *Cross-sectional study*—If applicable, describe analytical
11 methods taking account of sampling strategy

12 € Describe any sensitivity analyses
13

14 Continued on next page
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Yes (pages 17-18)
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Yes (pages 17-18)
		(b) Indicate number of participants with missing data for each variable of interest	Yes (table 1)
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	N/A
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	Yes (pages 17-18)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A

Discussion

Key results	18	Summarise key results with reference to study objectives	Yes (Page 22)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes (page 20)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes (page 20-22)
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes (page 22)

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes (page 25)
---------	----	---	---------------

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
4 available at www.strobe-statement.org.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024361.R3
Article Type:	Research
Date Submitted by the Author:	06-Dec-2018
Complete List of Authors:	Stack, Rebecca; Nottingham Trent University , Division of Psychology Nightingale, Peter; Queen Elizabeth Hospital Birmingham, Wellcome Trust Clinical Research Facility Jinks, Clare; Keele University, Arthritis Research UK Primary Care Centre Study Syndicate, DELAY Shaw, Karen; University of Birmingham, Institute of Applied Health Research Herron-Marx, Sandy; Independent Research Consultant Horne, Rob; UCL, UCL School of Pharmacy Deighton, Chris; Derby Teaching Hospitals NHS Foundation Trust Kiely, Patrick ; St George's University Hospitals NHS Foundation Trust Mallen, Christian; Keele University, Arthritis Research UK Primary Care Centre Raza, Karim; University of Birmingham, Institute of Inflammation and Ageing
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Health services research, Rheumatology
Keywords:	RHEUMATOLOGY, access to care, help seeking, health service research, rheumatoid arthritis

SCHOLARONE™
Manuscripts

1
2
3 **Title: Delays between the onset of symptoms and first rheumatology consultation in**
4
5 **patients with rheumatoid arthritis in the UK: an observational study**
6
7
8
9

10 **Authors**

11
12 Rebecca J Stack^{1,2}, Peter Nightingale³, Clare Jinks⁴, DELAY study syndicate, Karen Shaw⁵,
13
14 Sandy Herron-Marx⁶, Rob Horne⁷, Chris Deighton⁸, Patrick Kiely⁹, Christian D Mallen⁴ and
15
16 Karim Raza^{1,10}
17
18
19
20
21
22

23 **Department and Institutions**

- 24
25 1. Institute of Inflammation and Ageing, University of Birmingham, UK.
26
27 2. Division of Psychology, Nottingham Trent University, Nottingham, UK
28
29 3. Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation
30
31 Trust, Birmingham, UK.
32
33 4. Research Institute for Primary Care and Health Sciences, Keele University, UK.
34
35 5. Institute of Applied Health Research, University of Birmingham, UK
36
37 6. Independent Research Consultant, Brussels, Belgium.
38
39 7. School of Pharmacy, University of London, UK.
40
41 8. Department of Rheumatology, Derby Hospitals NHS Foundation Trust, Derby, UK.
42
43 9. Department of Rheumatology, St Georges University Hospital NHS Foundation Trust,
44
45 London, UK.
46
47 10. Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust,
48
49 Birmingham, UK.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Corresponding author**
4

5
6 Professor Karim Raza
7

8 Rheumatology Research Group
9

10 Institute of Inflammation and Ageing (IIA)
11

12 University of Birmingham
13

14 Queen Elizabeth Hospital, Birmingham, B15 2WB
15

16 E mail : k.raza@bham.ac.uk
17
18
19
20
21
22

23 **Word Count** (excluding title page, abstract, references and tables): 2499
24
25
26
27
28
29

30 **Keywords**
31

32 Rheumatoid arthritis; patient delay; Primary care delay; help-seeking; access to care;
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study.

A key strength of this study is that it surveyed a large sample of patients with new onset rheumatoid arthritis.

Participants were recruited from multiple NHS Trusts in the UK to identified delays in access to care.

Data on delay timepoints, demographic characteristics and consultation behaviour were gathered from multiple sources including patient self-report, healthcare professionals assessment and referral letters.

Limitations include the fact that data were collected at the point of diagnosis and information regarding key dates (in particular the onset of symptoms and presentation to primary care) were reliant on patient recall.

An additional limitation was that the interval between first consultation with a Rheumatologist and initiation of treatment was not measured.

Abstract

Objective: To investigate delays from symptom onset to rheumatology assessment for patients with a new onset of rheumatoid arthritis (RA) or unclassified arthritis.

Methods: Newly presenting adults with either RA or unclassified arthritis were recruited from rheumatology clinics. Data on the length of time between symptom onset and first seeing a GP (patient delay), between first seeing a GP and being referred to a rheumatologist (general practitioner delay) and being seen by a rheumatologist following referral (hospital delay) were captured.

Results: 822 patients participated (563 female, mean age 55 years). The median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4–26.3 weeks). Patients who purchased over the counter medications or used ice/heat packs took longer to seek help than those who did not. In addition, those with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset. The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks). Patients made a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Conclusion: This study identified delays at all levels in the pathway towards assessment by a Rheumatologist. However, delays in primary care were particularly long. Patient delay was driven by the nature of symptom onset. Complex multi-faceted interventions to promote rapid help seeking and to facilitate prompt onward referral from primary care should be developed.

Introduction:

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately 1% of the population.^{1,2} Rheumatoid arthritis is associated with significant morbidity in large part as a consequence of extra-articular co-morbidities associated with systemic inflammation. In the UK it has been estimated that RA costs the NHS around £560 million per year and that additional costs to the economy of sick leave and work-related disability total £1.8 billion per year.³ The first three months following the onset of RA symptoms represents an important therapeutic window.⁴ Treatment during this phase improves long-term clinical outcomes, increasing the proportion of patients whose disease enters remission, reducing RA related joint damage and reducing the eventual need for joint replacement surgery.⁵⁻¹⁰ Therefore, it is vital that patients are seen by Rheumatologists rapidly following the onset of RA symptoms to allow the rapid introduction of disease modifying anti-rheumatic drug treatment. However, despite increased recognition of the benefits of early treatment there remains considerable delay between symptom onset and the initiation of therapy.¹¹⁻¹³ Indeed a report by the UK's National Audit Office (NAO) in 2009 estimated that only 10% of patients with RA were treated within three months of symptom onset. The NAO's modelling suggested significant financial benefits for the broader economy and quality of life benefits for the individual if the proportion of patients treated earlier was increased.³

The patient's pathway to care can be delayed for a number of reasons, including delays on the part of the patient in recognising the significance of the early symptoms of RA.¹⁴⁻¹⁶ Recent

1
2
3 research has linked patients' perceptions of RA and coping styles to the length of time taken
4 to seek help.¹⁷ Before seeking medical help from a physician, patients may seek help from a
5 range of services including complementary therapists, pharmacists and telephone and on-line
6 services. However, the use of these services at the onset of inflammatory arthritis has not
7 been fully explored. Primary healthcare professionals often find the early symptoms of RA
8 difficult to distinguish from those of other rheumatic diseases, making timely and appropriate
9 referrals to rheumatologists challenging.^{18;19} There may thus be delays in healthcare
10 professionals making a referral to a Rheumatologist and also in assessment at the secondary
11 care level, contributing further to the delay in making a diagnosis and commencing
12 appropriate therapy.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 Several studies conducted across a range of countries have shown long delays between the
31 onset of symptoms and a patient's first consultation with a rheumatologist.²⁰⁻²³ However,
32 data related to lengths of time between the onset of inflammatory musculoskeletal
33 symptoms and first seeing a GP, between first seeing a GP and being referred to a
34 rheumatologist and being seen by a rheumatologist following referral were not available
35 across multiple NHS Trusts in multiple regions of the UK at the time of this study.

36 37 38 39 40 41 42 43 44 45 46 47 **Aim**

48
49 The aim of this study was to investigate the extents of delay in assessment of patients with
50 RA and unclassified arthritis. Specifically the study assessed extents of delay at the level of
51 the patient in seeking help from the general practitioner, the general practitioner in
52 referring to a Rheumatologist and the Rheumatologist in assessing the patient following
53 referral. The relationships between extents of delay and clinical and demographic variables
54
55
56
57
58
59
60

1
2
3 were explored and data captured relating to sources of information, help and advice utilized
4
5 by patients prior to GP consultation.
6
7
8
9

10 **Methods**

11
12 A questionnaire based survey of consecutively presenting patients with a new onset of RA or
13
14 unclassified inflammatory arthritis was undertaken in England and Scotland. Networks such
15
16 as the Early Rheumatoid Arthritis Network²⁴ and the National Institute for Health Research
17
18 Clinical Research Network²⁵ were used identify Rheumatology centres to participate in this
19
20 study. RJS also promoted the study during abstract presentations at British Society for
21
22 Rheumatology meetings.
23
24
25
26
27
28
29

30 Data were collected from Rheumatology departments in 34 NHS Trusts. Rheumatology
31
32 departments were secondary care based, although one rheumatology department
33
34 (Sandwell and West Birmingham Hospitals) operated clinics in both hospital and community
35
36 settings. Eligible patients were recruited on their first or second visit to the rheumatology
37
38 department following a primary care referral (data were not collected on the numbers of
39
40 patients whose data were collected at their first visit or at their second visit). Rheumatologists
41
42 were asked to approach consecutively presenting patients who met the eligibility criteria.
43
44
45
46 Eligible patients were newly referred adults (aged ≥ 18 years) with clinically apparent
47
48 synovial swelling of one or more joints who had either a new onset of RA (according to 2010
49
50 ACR / EULAR criteria ²⁶) or unclassified arthritis (UA; defined as a failure to fulfil classification
51
52 criteria for another inflammatory rheumatic disease). Patients with UA were recruited, as in
53
54 many cases patients with UA at initial secondary care assessment progress to RA over
55
56
57
58
59 time.²⁷
60

1
2
3
4
5
6 Data were collected using two questionnaires (available from the corresponding author on
7
8 request). First, following consent, the recruiting healthcare professional, with the patient
9
10 present, completed a questionnaire that captured data on extents of delays between [1]
11
12 symptom onset and seeing a healthcare professional (from herein referred to as 'patient
13
14 delay', these data was gathered from the patient's account by the recruiting healthcare
15
16 professional), [2] seeing a general practitioner and being referred to a rheumatologist (from
17
18 herein referred to as 'general practitioner e delay', these data was gathered from the
19
20 patient's account by the recruiting healthcare professional), and [3] being referred to a
21
22 rheumatologist and seeing a rheumatologist (from herein referred to as 'hospital delay',
23
24 these data were gathered from referral letters and hospital notes). Data were also gathered
25
26 on [1] demographic variables including the patient's age, gender, education, employment
27
28 status and postcode; deprivation ranks were calculated from postcode data using
29
30 Geoconvert 2010 which produced an Index of Multiple Deprivation (IMD) score,²⁸ [2] clinical
31
32 variables including the mode of symptom onset (palindromic (defined as intermittent
33
34 symptoms) vs. non-palindromic (defined as persistent symptoms)), rapidity of symptom
35
36 onset (acute vs. insidious; an acute onset was typically viewed as an onset of symptoms
37
38 which came on rapidly over 24-48 hours), duration of morning stiffness, swollen and tender
39
40 joint counts, Disease Activity Score 28 (DAS28) and fulfilment of 2010 ACR/EULAR criteria for
41
42 classification of RA²⁶.

43
44
45
46
47
48
49
50
51
52
53
54 In addition, via a separate questionnaire that patients completed by themselves, patients
55
56 provided data on actions taken in relation to their symptoms prior to seeking help from
57
58 primary care . The variables captured were informed by previous qualitative research,
59
60

1
2
3 including patient interviews and interviews with healthcare professionals. In addition, we
4
5 had input from Patient Research Partners and the questions asked were validated and
6
7 assessed for reliability²⁹.
8
9

10 11 12 **Patient and Public Involvement**

13
14
15 Patient and public involvement was an important element of this study. Patient
16
17 representatives from Sandwell and West Birmingham Hospitals NHS Trust were involved in
18
19 the study design, advised on the content of patient facing materials including participant
20
21 information sheets and consent forms and the content of questionnaires including
22
23 questions related to actions taken by patients prior to consulting their GPs. Patients were
24
25 members of the Project Management Group reviewing study recruitment and supporting
26
27 the Group in developing approaches to ensure that recruitment proceeded to time and
28
29 target
30
31
32
33
34
35
36
37

38 **Analysis**

39
40
41 To ensure that the data met parametric assumptions, the distribution and levels of
42
43 multicollinearity between variables were checked. Data on patient delays, general
44
45 practitioner delays and hospital delays were not normally distributed, therefore, log values
46
47 of these delay data were created to generate normally distributed variables.
48
49

50
51
52 For each of the outcomes patient delay, general practitioner delay and hospital delay a
53
54 general linear model was used with main effects and two-way interactions for the following
55
56 explanatory variables: gender, ethnicity, IMD score, age, education, employment status,
57
58 mode of onset, rapidity of onset, patient reported family history of RA and RA vs. UA. For
59
60

each outcome any two-way interactions which were not significant were removed in a backwards stepwise fashion, with the pairings with the highest p values being removed first. All main effects were retained, so that the final model for each outcome included all ten explanatory variables and any significant two-way interactions ($p < 0.01$). All significant main effects and interactions are reported in the Results section.

Results

1. Participant characteristics

Data were collected from 856 patients between 2011 and 2014. Patients were withdrawn from the study due to incomplete data (21 cases) and ineligibility (13 cases in whom there was no clinical synovitis reported at recruitment). Data were thus analysed from 822 patients of whom 68.5% were female with a mean age of 55 years. Characteristics of patients are presented in table 1.

Table 1: Demographic and disease related characteristics of patients. Data are presented as either percentage (number) or median (IQR) as appropriate. Tender joint count is out of 42 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 hip, 2 knee, 2 ankle, 10 MTP). Swollen joint count is out of 40 joints (10 PIP, 10 MCP, 2 wrist, 2 elbow, 2 shoulder, 2 knee, 2 ankle, 10 MTP).

Female	68.5% (563)
Age, years	57 (45-67)
Diagnosis of RA	73% (603)
Ethnicity: Black British	6.0% (49)

South Asian	7.7% (63)
White British	84.9% (698)
Other	1.5% (12)
Self-reported family history of RA	34.9% (287)
Palindromic onset	42.8% (352)
Acute onset	35.9% (295)
Duration of morning stiffness, minutes	60 (10-120)
DAS28	4.88 (3.98 -5.80)
HAQ	1.13 (0.50-1.73)
Tender joint count	9 (4-18)
Swollen joint count	5 (2-10)

2. Intervals between symptom onset and first rheumatology consultation

Overall the median time between symptom onset and seeing a rheumatologist was 27.2 weeks (IQR 14.1 – 66 weeks); only 20% of patients were seen within the first 3 months following symptom onset. The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks). The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks) with patients making a mean of 4 GP visits before being referred. The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

1
2
3 *Palindromic onset is defined as intermittent symptoms, while non-palindromic is defined as persistent*
4 *symptoms. Acute onset defined as symptoms which came on rapidly over 24-48 hours, while insidious*
5 *onset is defined as symptoms which developed slowly over an extended period of time. Patients*
6
7
8
9
10 with a palindromic symptom onset had a significantly longer patient delay than those with a
11
12 non-palindromic onset (9.3 weeks (IQR 2-43 weeks) vs 4.3 weeks (IQR 1-17 weeks); $p < 0.001$,
13
14 t-test). Furthermore, those with an acute symptom onset had significantly shorter patient
15
16 delays than those with an insidious symptoms onset (2.4 weeks (IQR 1 - 6.6 weeks) vs 11.1
17
18 weeks (IQR 4-44 weeks; $p < 0.001$, t-test).
19
20
21
22
23
24
25

26 *Resources used before seeking help from primary care*

27
28
29 Patients reported taking a range of actions in relation to their symptoms before seeking help
30
31 from their GP and in some cases these actions were associated with longer delays in GP
32
33 consultation (see table 2). Most often patients reported purchasing tablets from 'the
34
35 chemist', although only a small proportion actually reported speaking to a pharmacist.
36
37
38 Other actions reported by patients included applying heat or cold packs to joints or buying
39
40 joint supports.
41
42
43
44
45
46
47

48 **Table 2.** *Actions taken by patients with inflammatory arthritis before seeking help from their*
49 *GP with comparison made for patient delay between those who did and did not undertake*
50 *this action using independent t-tests; * P value for comparison of those who did and did not*
51 *undertake this action.*
52
53
54
55
56
57
58
59
60

Actions taken before seeking help from GP	% (number) of participants undertaking this action	Median (IQR) patient delay in weeks for those undertaking this action	Median (IQR) patient delay in weeks for those not undertaking this action	P value
Bought tablets from the chemist	51.1% (273 out of 534)	6.9 (2-30.7)	4.7 (1.4-23)	p=0.036
Used an ice or heat pack on joint	47.8% (254 out of 531)	7.6 (2-30.3)	4.9 (2-26.1)	p=0.045
Took baths	47.4% (251 out of 529)	6.3 (2-30.4)	5.6 (2-26.1)	p=0.473
Bought joint supports (splints, tubi-grips etc)	37.4% (198 out of 529)	4.4 (2.1-18.6)	5.1 (2-26.9)	p=0.362
Used alternative therapies	25.2% (134 out of 531)	8.3 (2-42.1)	5.3 (2-26.3)	p=0.020
Bought products from a health shop	19.0% (101 out of 532)	5.9 (2-36.3)	5.9 (2-26)	p=0.182
Modified diet	14.4% (76 out of 529)	6 (2.1-35.3)	6.1(2-26.3)	p= 0.183

Used prayer or sought spiritual guidance	8.4% (45 out of 534)	4.4 (2.1-18.6)	6.3 (2-26.9)	p=0.941
Spoke to a pharmacist	7.9% (41 out of 521)	5.9 (2-38.1)	5.9 (2-26.3)	p=0.544

Thirty-seven percent of patients reported looking on the internet (for example visiting the NHS direct website, BUPA website, Arthritis Research UK website and searching for information using search engines such as Google). Patients also reported seeking support via a telephone helpline; 5.7% described calling the NHS direct helpline or another telephone health advice service. 3.7% sought help in the workplace (e.g. from an occupational nurse), 2% of patients went directly to the Accident and Emergency Department and 1% attended an NHS walk-in centre.

Multivariate analysis: Patient delay

The interaction model showed main effects for mode of onset (palindromic vs. non-palindromic; $F=26.65$, $P<0.01$) and rapidity of onset (acute vs. insidious; $F=65.36$, $P<0.01$). An interaction was found between palindromic onset and gender ($F=45.658$, $P<0.01$); men with a palindromic onset waited significantly longer before seeking help.

Multivariate analysis: General practitioner delay

A main effect was found for ethnicity ($F=6.26$, $P<0.01$). Significant differences in general practitioner delay were found between White British and South Asian patients (6.2 weeks (IQR 2-18.6) vs 22 weeks (IQR 6.5-39.8); $P<0.001$) and between White British and Black British patients (6.2 weeks (IQR 2-18.6) vs 11.1 weeks (IQR 4.3-21.7); $P<0.001$). No significant difference was found between South Asian and Black British patients ($P=1.000$).

A main effect was also found for family history ($F=5.89$, $P<0.01$); the median general practitioner delay for those with a self-reported family history of RA was 9 weeks (IQR 2.4-25.7), while general practitioner delay for those with no family history was 6.3 weeks (IQR 2.3-19). Interactions at a statistically significant level (<0.01) were not found.

Multivariate analysis: Hospital delay

The original model included main effects and two-way interactions for the following explanatory variables: gender, ethnicity, IMD score, age, education, employment status, mode of onset, rapidity of onset, family onset and RA vs. UA. None of the main effects or interactions (when removed backwards) were significant in predicting the delay between referral and being seen in secondary care.

Discussion

International guidelines recommend that the treatment of RA should begin as soon as possible after the onset of symptoms, ideally aiming to capture patients within the first 3 months following symptom onset. However, this large UK study of delays in access to care for RA patients found that the median patient delay in seeking help at the onset of symptoms was 5.4 weeks, while the median delay between seeing a healthcare professional and being referred was 6.9 weeks. Our study highlights that only 20% of patients were seen within the first 3 months of symptom onset. This appears to be lower than the rate reported in other European countries for example a recent study in Austria reported that 38% of patients were seen within the first 3 months³⁰. The present study also found an average delay of 4.7 weeks from referral until the patient was seen by a rheumatologist, similar to figures reported in the NAO report³. Unlike our previous study conducted at a single centre in the UK where patient delay accounted for the largest element of delay,¹³ we found that GP delay was the largest contributor to overall delay; patient delay was less than we had previously reported in our single centre study.

This research highlights that delays in primary care are long, and a major contributor to overall delays between symptom onset and the first rheumatology visit. General practitioners are faced with a number of barriers to identifying patients with newly presenting RA including the often non-specific nature of symptoms at the earliest stages of RA.¹⁸ Research is underway to define symptom complexes most predictive of RA development in patients with newly presenting musculoskeletal symptoms. For example, a questionnaire has been developed and validated to capture such symptoms in patients

1
2
3 presenting with joint symptoms which by history are suggestive of an underlying
4
5 inflammatory cause³¹ and data are currently being collected from such patients in secondary
6
7 care based longitudinal observational cohort studies to identify symptoms that may predict
8
9 RA development. Furthermore an assessment of primary care databases has identified a
10
11 range of symptoms including hand related joint symptoms, morning stiffness and carpal
12
13 tunnel syndrome type symptoms as being ones with which patients frequently present to
14
15 the GP prior to the point at which the GP refers the patient to a Rheumatologist or records a
16
17 diagnosis of RA ³² It is likely that a combination of education, and evidence based referral
18
19 algorithms, will be needed to ensure that suspected cases are referred early. For example,
20
21 in Fife, Scotland GPs did not have access to rheumatoid factor testing during the course of
22
23 our study, and used guidelines with pictorial representations to help identify early synovitis
24
25 (personal communication Dr Helen Harris). Fife was a participating centre in this study, and
26
27 was found to have the lowest GP referral time of all centres surveyed. Furthermore,
28
29 facilitating access to secondary care, for example through the establishment of rapid
30
31 assessment clinics whose main aim is to identify whether the patient does or does not have
32
33 synovitis have been shown to significantly reduce delays in the assessment of patients.³³ A
34
35 limitation of our research is that the study was not able to assess regional differences across
36
37 NHS Trusts. A study comparing delays and referral patterns between hospitals with local
38
39 policies and practices which may influence the time between onset and first consultation
40
41 would be useful and an international study would be particularly helpful. In addition, this
42
43 study did not examine the distances between patients' homes and their local GP surgeries,
44
45 and hospital and so we were unable to assess whether physical distance between the
46
47 patient's home and the GP surgery or hospital influenced delay.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A number of factors were found to influence GP delay including ethnicity. Studies in the field
4
5 of oncology have also found that people from ethnic minority backgrounds face longer GP
6
7 delays.^{34;35} In the context of RA it is possible that the early symptomatology of patients from
8
9 ethnic minority backgrounds is different from, and less typical of RA than that of, patients of
10
11 white British background, thus making recognition more challenging for GPs. Data certainly
12
13 exist that the clinical phenotype of established RA differs in patients of South Asian origin
14
15 compared with patients of White British origin,³⁶ though data relating the clinical
16
17 presentations of RA in these groups are lacking. Furthermore, it is unclear why a self-
18
19 reported family history of RA would be associated with longer delays although it is
20
21 important to recognise that GPs may not have elicited this information from the patient.³⁷
22
23 Qualitative approaches may be helpful to address some of these issues in the future.
24
25
26
27
28
29
30
31

32
33 Previous qualitative studies and a meta-synthesis have identified barriers to help seeking at
34
35 the onset of RA.³⁷⁻⁴³ The present study identifies that before seeking formal medical
36
37 attention, people experiencing the early symptoms of RA seek information and help from a
38
39 number of alternative sources and often self-medicate. We identified that buying tablets
40
41 from a pharmacy, and using heat or ice on joints was significantly associated with longer
42
43 patient delays. This finding highlights that some self-management behaviours, particularly
44
45 those linked to accessing pharmacy services can negatively impact on the time it takes to
46
47 seek help; this needs further exploration. Factors previously suggested to be associated
48
49 with delays in GP consultation included an insidious onset of mild symptoms and a lack of
50
51 knowledge about RA, personal susceptibility to RA and the availability of treatments to slow
52
53 disease progression. In our national sample 64.1% of people describe an insidious onset of
54
55 RA, and 42.8% describe a palindromic onset of RA. Therefore, majority large proportion of
56
57
58
59
60

1
2
3 patients surveyed experienced a slow and / or intermittent onset of their inflammatory joint
4
5 symptoms. Our quantitative data are thus consistent with results from qualitative studies,
6
7 demonstrating that the mode and rapidity of onset of symptoms is significantly associated
8
9 with patient delays.
10
11

12
13 This study has a number of limitations. Firstly, the interval between first consultation with a
14
15 Rheumatologist and initiation of disease modifying anti-rheumatic drug (DMARD) treatment
16
17 was not measured. Any additional delay in commencing DMARD treatment will negatively
18
19 impact the patient and variables associated with delays at this level should be assessed in
20
21 future studies. Secondly, during the course of this study a number of guidelines related to
22
23 RA management were published which may have influenced practice, and patterns of
24
25 referral. We were not able to explore the relationships between the availability / local
26
27 adoption of guidelines and delays in the assessment of patients. Future investigation should
28
29 assess the impact of policy changes on patterns of help-seeking, referral and assessment.
30
31
32 Thirdly, the rheumatology centres participating in this study were self-selecting, therefore,
33
34 there may be biases in the characteristics of the rheumatology centres which participated in
35
36 this study. For example, the participating rheumatology units may have had a particular
37
38 interest in early arthritis. Only a study which recruited consecutive patients from all
39
40 rheumatology units across the UK would be able to provide a truly national picture.
41
42
43 Fourthly, whilst we were able to document the length of delay at a primary care level there
44
45 were important variables which may have influenced this delay which we did not record and
46
47 so were unable to explore. For example it would have been helpful have access to results
48
49 tests performed in primary care to assess whether levels of inflammatory markers or RA
50
51 related autoantibodies measured in primary care influenced the rapidity of referral from
52
53 primary care. Indeed a recent quantitative survey of GPs' anticipated actions in primary care
54
55
56
57
58
59
60

1
2
3 when dealing with patients with suspected RA suggest that results of these tests may
4 influence GP behaviours⁴⁴. Future research should address this. Similarly, a number of
5 secondary care related variables may have influenced the extent of secondary care delay
6 including the number of rheumatologists at each Trust, whether a dedicated early arthritis
7 clinic was in place and approaches taken to the triage of referrals. Data relating to these
8 variables were not collected though future work addressing issues of delay should address
9 these important issues. Fifthly, data relating to the dates of onset of symptoms and initial
10 GP consultation were gathered from patients' histories, and therefore relied on patient
11 recollection with a possible associated error. However, a previous study addressing delays in
12 the assessment of patients with RA, compared patient accounts of their journeys to first
13 rheumatology consultation against medical records and highlighted the accuracy of patient
14 recollection in relation to dates found to be documented in primary care records⁴⁵. This, to
15 some extent, validates our approach of using patient memory to define the dates of
16 symptom onset and initial GP presentation. An alternative approach would be a
17 longitudinal observational study in the general population to track the development of
18 symptoms and the relationship between that and GP consultation, GP referral and
19 secondary care assessment. A challenge with this approach is the low incidence of RA and
20 thus the requirement for a very large sample size. One could potentially enrich the
21 population for RA risk by, for example, following individuals who are at increased risk of RA
22 (e.g. the first degree relatives of patients with RA). However, one of the challenges with this
23 strategy is that simply being involved in such a study may influence subsequent patient and
24 GP behaviour.

1
2
3 Whilst delays in primary care are the largest contributor to overall delay, patient delay and
4 hospital delay represent important components. This study found that the nature of
5
6 symptoms onset influenced how quickly patients with RA sought help, suggesting that those
7
8 with an acute onset of persistent symptoms seek help faster than those with insidious and
9
10 palindromic onsets. Interventions to encourage rapid help seeking should consider
11
12 highlighting the frequently insidious onset of RA to members of the public stressing that
13
14 help should be sought even when symptoms are mild. However, even those with a rapid
15
16 onset of persistent symptoms often delayed for prolonged periods before seeking help. We
17
18 have previously shown that members of the public view musculoskeletal symptoms, even
19
20 those with clear inflammatory features, as less worrisome and less requiring rapid
21
22 assessment as compared with symptoms of other common diseases such as ischaemic type
23
24 chest pain or bowel disturbance with associated rectal blood loss⁴⁶. Enhanced public
25
26 education to highlight the significance of inflammatory type musculoskeletal symptoms is
27
28 thus likely to be needed. Interventions at multiple levels, including at the levels of the
29
30 public, the services which members of the public consult after the onset of symptoms (e.g.
31
32 pharmacies), primary care and secondary care will be needed to reduce overall delays in
33
34 access to appropriate specialists.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests

No competing Interest:

Contributorship

RJS, CJ, SHM, CDM, KS, RH, CD, PK and KR made substantial contributions to the conception or design of the work. The acquisition of data was undertaken by RJS, KR, PK and CD. RJS, CJ and SHM facilitated patient and public involvement in the design, delivery and interpretation of this study. The analysis and interpretation of data were undertaken by RJS, PN and KR. RJS, PN, CJ, SHM, CDM, KS, RH, CD, PK and KR were involved in drafting the work and revising it critically for important intellectual content. RJS, CJ, SHM, CDM, KS, RH, CD, PK and KR gave final approval of the version published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgements

We would like to thank the staff at the rheumatology departments who collected data for this study. We would also like to thank patient research partners at Sandwell and West Birmingham Hospitals NHS Trust for their help and support with this study.

Funding information

This article presents independent research funded in part by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (funder's reference PB-PG-1208-18114). CDM is funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research and a NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). CJ is part-funded by the NIHR Collaborations for Leadership in Applied Health Research and Care West Midlands. RH is part-funded by North Thames CLAHRC and his contribution was also supported by an NIHR Senior Investigator Award. KS is funded by the NIHR CLAHRC West Midlands initiative. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Ethical approval information Ethical approval was obtained from South Birmingham Research Ethics Committee (reference no. 10/H1207/98) and all participants gave written

1
2
3 informed consent. Data was stored in a secure location and protected by multiple security
4 systems.
5
6
7

8 **Data sharing statement**

9
10 Data are available upon request from the corresponding author.
11
12
13

14 **Exclusive Licence**

15
16 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work
17 (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
18 contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY
19 licence shall apply, and/or iii) in accordance with the terms applicable for US Federal
20 Government officers or employees acting as part of their official duties; on a worldwide,
21 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and
22 where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the
23 Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).
24
25
26
27
28

29
30 The Submitting Author accepts and understands that any supply made under these terms is
31 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
32 employer or a postgraduate student of an affiliated institution which is paying any applicable
33 article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes
34 to make the Work available on an Open Access basis (and intends to pay the relevant APC), the
35 terms of reuse of such Open Access shall be governed by a Creative Commons licence – details
36 of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our
37 licence referred to above.
38
39
40
41
42
43

44 **Non-author contributors - Delay study syndicate**

45
46
47 Sandwell and West Birmingham Hospitals NHS Trust: Biruk Asfaw, Sabrina Kapoor, Kanta
48 Kumar, Adam Slater & Christopher Buckley

49
50 Derby Teaching Hospitals NHS Foundation Trust: Chris Deighton & Alison Booth

51
52 Nottingham University Hospitals NHS Trust: Marie-Josophe Pradere, Ira Pande & Ian
53
54 Gaywood

55
56 St George's University Hospitals NHS Trust: Francesca Leone & Patrick Keily

57
58 Lancaster Teaching Hospitals NHS Foundation Trust: Bronwen Evans & Marwan Bukhari

59
60 Poole Hospitals NHS Foundation Trust: Julia Taylor, Helena Knowles, & Sarah Westlake

1
2
3 University Hospitals Coventry and Warwickshire NHS Trust: Tanya Potter
4
5 Sherwood Forest Hospitals NHS Foundation Trust: Debbie Wilson, Jayne Smith & David
6
7 Walsh
8
9 King's College Hospitals NHS Foundation Trust: Nyarko Ahwireng, Audu Aderonke & David
10
11 Scott
12
13 Guy's and St Thomas NHS Foundation Trust: Louise Nel, Naomi Hare & Andrew Cope
14
15 North Bristol NHS Trust: Julie Taylor, Wendy Wilmott & Paul Creamer
16
17 West Hertfordshire Hospitals NHS Trust: Lynn Currie, Adam Young & Karen Markwell
18
19 Lewisham and Greenwich NHS Trust: Louise Pollard & Debbie Johnson
20
21 Royal Surrey Country NHS Foundation Trust: Stephanie Allen & Raad Makadsi
22
23 Hampshire Hospitals NHS Foundations Trust: Peter Prouse & Janet Cushnaghan
24
25 University Hospitals of Leicester NHS Trust: Jessy Sabu & Moorthy Arumugam
26
27 County Durham and Darlington NHS Foundation Trust: Matt Bridges & Pam Race
28
29 Weston Area Health NHS Trust: Dawn Symonds & Matt Bridges
30
31 University Hospitals Birmingham NHS Foundation Trust: Jackie Cobb, Andrew Filer, Simon
32
33 Bowman & Paresh Jobanputra
34
35 Royal Wolverhampton Hospital NHS Trust (at the time of recruitment the hospital from
36
37 which patients were recruited was within the Mid Staffordshire NHS Foundation Trust) :
38
39 Julie Edwards & Tom Sheeran
40
41 East Kent Hospitals University NHS Foundation Trust: Caroline Crowley & Imad Jassim
42
43 University Hospitals of the North Midlands NHS Trust: Julie Gray & Jon Packham
44
45 NHS Fife: Paul Allcoat & Helen Harris
46
47 Yeovil District Hospital NHS Foundation Trust: Rebecca Rowland & Sally Knights
48
49 Northumbria Healthcare NHS Foundation Trust AND The Newcastle Upon Tyne Hospitals
50
51 NHS Foundation Trust: Peta Heslop, Sandra Robinson, David Walker, Heather Russell &
52
53 Sheryl Mitchell
54
55 Chesterfield Royal Hospital NHS Foundation Trust: Heather Cripps & Kevin Fairburn
56
57 Lancashire Teaching Hospitals NHS Foundation Trust AND East Lancashire Hospital NHS
58
59 Trust: Sue Cotterell, Gillian Welch, Ayesha Madan & Lee Suan Teh
60
61 Cambridge University Hospitals NHS Foundation Trust: Lucy Winstanley & Shweta Bhagat
62
63 The Dudley Group NHS Foundation Trust: Lucy Kadiki, Chitra Ramful & Ravinder Sandhu
64
65 Royal Cornwall Hospitals NHS Trust: Amanda Datson, & Anthony Woolf
66

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference List

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(1) Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2012; 72(8):1315-1320.

(2) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002; 41(7):793-800.

(3) National Audit Office. Services for people with rheumatoid arthritis. National Audit Office . 2009. London, The Stationery Office. 24-1-2013.

(4) van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. *Ann Rheum Dis* 2015; 74(5):806-812.

(5) Feldman DE, Bernatsky S, Houde M, Beauchamp ME, Abrahamowicz M. Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery? *Rheumatology (Oxford)* 2013; 52(3):452-459.

(6) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906-914.

(7) Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2006; 20(5):849-863.

(8) Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? *Ann Rheum Dis* 2015; 74(5):793-794.

(9) Scott DL, Hunter J, Deighton C, Scott DG, Isenberg D. Treatment of rheumatoid arthritis is good medicine. *BMJ* 2011; 343:d6962.

(10) van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW et al. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum* 2010; 62(12):3537-3546.

(11) Feldman DE, Bernatsky S, Haggerty J, Leffondre K, Tousignant P, Roy Y et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2007; 57(8):1419-1425.

(12) Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009; 48(1):57-60.

(13) Kumar K, Daley E, Carruthers DM, Situnayake D, Gordon C, Grindulis K et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. *Rheumatology (Oxford)* 2007; 46(9):1438-1440.

- 1
2
3 (14) Stack RJ, Simons G, Kumar K, Mallen CD, Raza K. Patient delays in seeking help at the onset
4 of rheumatoid arthritis: the problem, its causes and potential solutions. *Aging Health* 2013;
5 9(4):425-435.
6
7 (15) Oliver S, Bosworth A, Airoldi M, Bunyan H, Callum A, Dixon J et al. Exploring the healthcare
8 journey of patients with rheumatoid arthritis: a mapping project - implications for practice.
9 *Musculoskeletal Care* 2008; 6(4):247-266.
10
11 (16) Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, Hazes JM et al. A systematic
12 literature review of strategies promoting early referral and reducing delays in the diagnosis
13 and management of inflammatory arthritis. *Ann Rheum Dis* 2012; 27(1):13-22.
14
15 (17) Van der Elst K, De CD, Vecoven E, Arat S, Meyfroidt S, Joly J et al. Are illness perception and
16 coping style associated with the delay between symptom onset and the first general
17 practitioner consultation in early rheumatoid arthritis management? An exploratory study
18 within the CareRA trial. *Scand J Rheumatol* 2015;1-8.
19
20 (18) Stack RJ, Llewellyn Z, Deighton C, Kiely P, Mallen CD, Raza K. General practitioners'
21 perspectives on campaigns to promote rapid help-seeking behaviour at the onset of
22 rheumatoid arthritis. *Scand J Prim Health Care* 2014; 32(1):37-43.
23
24 (19) Stack RJ, Shani M, Mallen CD, Raza K. Symptom complexes at the earliest phases of
25 rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013;
26 65(12):1916-1926.
27
28 (20) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed
29 analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis
30 patients. *Scand J Rheumatol* 2014; 43(1):1-8
31
32 (21) van Nies JA, Brouwer E, de Rooy DP, van Gaalen FA, Huizinga TW, Posthumus MD et al.
33 Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. *Ann*
34 *Rheum Dis* 2013; 72(8):1302-1307.
35
36 (22) Zafar S, Badsha H, Mofti A, Delosantos A, Altares J, Matudio G et al. Efforts to increase public
37 awareness may result in more timely diagnosis of rheumatoid arthritis. *J Clin Rheumatol*
38 2012; 18(6):279-282.
39
40 (23) Nanji JA, Choi M, Ferrari R, Lyddell C, Russell AS. Time to consultation and disease-modifying
41 antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta
42 perspective. *J Rheumatol* 2012; 39(4):707-711.
43
44 (24) Garwood W. The Early Rheumatoid Arthritis Network (ERAN). *Musculoskeletal care*. 2004
45 Nov;2(4):240-4.
46
47 (25) The National Institute for Health Research Clinical Research Network.
48 <https://www.nihr.ac.uk/about-us/how-we-are-managed/managing-centres/crn/> (accessed
49 16th August 2018)
50
51 (26) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III et al. 2010 rheumatoid
52 arthritis classification criteria: an American College of Rheumatology/European League
53 Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010; 69(9):1580-1588.
54
55
56
57
58
59
60

- 1
2
3 (27) van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al.
4 Validation of a prediction rule for disease outcome in patients with recent-onset
5 undifferentiated arthritis: moving toward individualized treatment decision-making. *Arthritis*
6 *Rheum* 2008; 58(8):2241-2247.
7
8 (28) Midas. GeoConvert. <http://geoconvert.mimas.ac.uk>. 2010.
9
10
11 (29) Stack RJ, Mallen CD, Deighton C, Kiely P, Shaw KL, Booth A et al. The development and initial
12 validation of a questionnaire to measure help-seeking behaviour in patients with new onset
13 rheumatoid arthritis. *Health Expect* 2014; Jun(3):1-10.
14
15 (30) Puchner R, Janetschko R, Kaiser W, Linkesch M, Steininger M, Termetsberger R et al. Efficacy
16 and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort
17 Study. *Journal of Rheumatology* 2016; 43(6):1130-1135.
18
19 (31) van Beers-Tas MH, ter Wee MM, van Tuyl LH, Maat B, Hoogland W, Hensvold AH, Catrina AI,
20 Mosor E, Stamm TA, Finckh A, Courvoisier DS. Initial validation and results of the Symptoms
21 in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project. *RMD*
22 open. 2018 May 1;4(1):e000641.
23
24 (32) Muller S, Hider S, Machin A, Stack R, Hayward RA, Raza K, Mallen C. Searching for a
25 prodrome for rheumatoid arthritis in the primary care record: A case-control study in the
26 clinical practice research datalink. In Seminars in arthritis and rheumatism 2018 Jun 23. WB
27 Saunders.
28
29 (33) van Nies JA, Brouwer E, van Gaalen FA, Allaart CF, Huizinga TW, Posthumus MD et al.
30 Improved early identification of arthritis: evaluating the efficacy of Early Arthritis
31 Recognition Clinics. *Ann Rheum Dis* 2012; 72(8):1295-301.
32
33 (34) Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in
34 breast cancer diagnosis by race, socioeconomic status, age and year. *Br J Cancer* 1992;
35 65(6):922-926.
36
37 (35) Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast
38 cancer diagnosis in young women by race/ethnicity. *JAMA Surg* 2013; 148(6):516-523.
39
40 (36) Griffiths B, Situnayake RD, Clark B, Tennant A, Salmon M, Emery P. Racial origin and its effect
41 on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched
42 cross-sectional study. *Rheumatology (Oxford)* 2000; 39(8):857-864.
43
44 (37) Kumar K, Daley E, Khattak F, Buckley CD, Raza K. The influence of ethnicity on the extent of,
45 and reasons underlying, delay in general practitioner consultation in patients with RA.
46 *Rheumatology (Oxford)* 2010; 49(5):1005-1012
47
48 (38) Tiwana R, Rowland J, Fincher M, Raza K, Stack RJ. Social interactions at the onset of
49 rheumatoid arthritis and their influence on help-seeking behaviour: A qualitative
50 exploration. *British journal of health psychology*. 2015 Sep;20(3):648-61.
51
52 (39) Mølbæk K, Hørslev-Petersen K, Primdahl J. Diagnostic delay in rheumatoid arthritis: a
53 qualitative study of symptom interpretation before the first visit to the doctor.
54 *Musculoskeletal care*. 2016 Mar;14(1):26-36.
55
56
57
58
59
60

- 1
2
3 (40) Simons G, Mallen CD, Kumar K, Stack RJ, Raza K. A Qualitative Investigation of the Barriers to
4 Help-seeking Among Members of the Public Presented with Symptoms of New-onset
5 Rheumatoid Arthritis. *J Rheumatol* 2015; 42(4):585-592.
6
7 (41) Sheppard J, Kumar K, Buckley CD, Shaw KL, Raza K. 'I just thought it was normal aches and
8 pains': a qualitative study of decision-making processes in patients with early rheumatoid
9 arthritis. *Rheumatology (Oxford)* 2008; 47(10):1577-1582.
10
11 (42) Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the
12 onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative
13 literature. *Ann Rheum Dis* 2012; 71(4):493-497.
14
15 (43) Townsend A, Wyke S, Hunt K. Self-managing and managing self: practical and moral
16 dilemmas in accounts of living with chronic illness. *Chronic Illn* 2006; 2(3):185-194.
17
18 (44) Scott IC, Mangat N, MacGregor A, Raza K, Mallen CD, Hider SL. Primary care challenges in
19 diagnosing and referring patients with suspected rheumatoid arthritis: a national cross-
20 sectional GP survey. *Rheumatology Advances in Practice*. 2018 Apr 6;2(1):rky012.
21
22 (45) De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. A detailed
23 analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis
24 patients. *Scand J Rheumatol* 2014; 43(1):1-8.
25
26 (46) Simons G, Belcher J, Morton C, Kumar K, Falahee M, Mallen CD, Stack RJ, Raza K. Symptom
27 Recognition and Perceived Urgency of Help-Seeking for Rheumatoid Arthritis and Other
28 Diseases in the General Public: A Mixed Method Approach. *Arthritis care & research*. 2017
29 May;69(5):633-41.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes (Page 1)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes (page 4)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes (pages 5-7)
Objectives	3	State specific objectives, including any prespecified hypotheses	Yes (pages 6-7)
Methods			
Study design	4	Present key elements of study design early in the paper	Yes (page 1, and page 7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes (page 7- 9)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Cross-sectional study – Yes (Page 7)
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
Variables	7	<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Yes (page 7-8)
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes (page 7-8, also see table 1)
Bias	9	Describe any efforts to address potential sources of bias	Yes (Pages 17-22)
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes (page 10)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes (page 10)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(b) Describe any methods used to examine subgroups and interactions

Yes

(c) Explain how missing data were addressed

(d) *Cohort study*—If applicable, explain how loss to follow-up was addressed

N/A

Case-control study—If applicable, explain how matching of cases and controls was addressed

Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy

€ Describe any sensitivity analyses

Continued on next page

For peer review only

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Yes (pages 17-18) N/A N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Yes (pages 17-18) Yes (table 1) N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A N/A Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A Yes (pages 17-18) N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Yes (Page 22)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes (page 20)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes (page 20-22)
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes (page 22)
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes (page 25)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only